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Robert Richard Flavell, PhD 
The Rockefeller University, 2009 
 
Leptin is a polypeptide hormone, secreted principally by adipose tissue, which 
functions as an afferent signal in a feedback loop to maintain body weight and energy 
homeostasis. In addition to its well documented effects on food intake and energy 
expenditure, leptin modulates the function of many other physiological systems in 
mammals, through actions in the central nervous system and periphery. Remarkably, 
despite extensive studies on leptin receptor expression, the physiological biodistribution 
of the hormone remains essentially unknown. In order to characterize the distribution 
leptin in mammals, we have developed methodologies to radiolabel the hormone and 
visualize its biodistribution using positron emission tomography (PET). Two 
complementary techniques were developed to label leptin using the positron emitting 
isotopes 68Ga and 18F. 68Ga labeling was accomplished by lysine-directed conjugation 
with the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 
followed by chelation of the isotope. 18F labeling was accomplished using a site-specific, 
two step labeling procedure in which an aminooxy moiety was introduced at the C-
terminus of leptin using expressed protein ligation (EPL), which was subsequently 
derivitized with 18F-4-fluorobenzaldehyde in an aniline accelerated radiochemical 
oximation reaction. These probes were used for PET imaging in mice, rats, and in rhesus 
macaques. PET imaging in these organisms revealed that the hormone was rapidly taken 
up by the cortex of the kidney, bone marrow, and visceral organs. Uptake in the kidney 
was partially saturable with cold ligand, and was not mediated by leptin receptor (ObR). 
Subsequent analysis in with a kidney specific knockout of the multiligand endocytic 
transporter megalin revealed loss of leptin in the urine, which was confirmed using PET 
imaging. Thus, megalin is required for the uptake of leptin in the proximal convoluted 
tubule within the cortex of the kidney. Subsequent biodistribution experiments revealed 
that the hormone was taken up by the brain, spleen, liver, fat, and lungs in mice, and that 
this uptake was leptin receptor dependant. Furthermore, PET imaging in rhesus macaques 
revealed that leptin was absorbed by the bone marrow and liver. Thus, leptin may activate 
and modulate hematopoiesis by direct action on either hematopoietic precursors or the 
stromal support tissue. Thus, novel physiologically significant interactions of the 
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Chapter 1. Introduction 
 
1.1 Leptin: a circulating factor regulating fat homeostasis 
 
 Energy and body weight homeostasis in mammals is regulated with remarkable 
precision. While an average man takes in approximately one million kcal per year, the 
expected weight gain of the same individual is under 0.5 kilograms, an energy increase of 
only 1560 kcal. This small weight gain represents only 0.2% of energy intake1. Thus, 
food intake and energy expenditure must be nearly equal, suggesting the existence of a 
feedback system which regulates this coupling. Nevertheless, there is a clear variation in 
the set point of this system between individuals. Obesity is defined as a body mass index 
(BMI, defined as the weight of an individual in kg/height in m squared) of over 30, and is 
associated with significant health risks, most prominently cardiovascular disease and 
diabetes2. Obesity has increased dramatically worldwide over the last 30 years, and 
current estimates suggest that at least 35% of adults in the United States are obese3. A 
series of studies on twins have revealed that the variation in body weight is 50-90% 
genetic, a factor underappreciated by the general public4. Nevertheless, there is a 
continual increase in average BMI and obesity, implying that environmental factors must 
also play a role. Thus, obesity is a result of genetic susceptibility, coupled with an 
“obesigenic” environment in which inexpensive, high calorie, palatable foods are readily 
available5. An understanding of these genetic and environmental factors, and the 
development of effective interventions to control them, is of paramount importance for 
public health in the 21st century. 
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The role of the hypothalamus in body weight and energy homeostasis has been 
known since the 1940’s. Bilateral lesions introduced in rats in the lateral hypothalamus 
completely inhibited food intake to the point that the animals die of starvation6. 
Conversely, lesions in the ventromedial nucleus of the hypothalamus cause hyperphagia. 
Based on these observations, Kennedy proposed the existence of a circulating factor 
which could signal the level of fat to the hypothalamus7. The spontaneously occurring 
obese mouse mutants ob and db (named for obese and diabetes) provided additional clues 
about the nature of these factors. By fusing the circulatory systems of ob and wild type 
animals (parabiosis), the obese phenotype of the ob animal could be abrogated8. By 
contrast, the db mouse did not lose weight when parabiosed with the wild type animal. In 
fact, the animal fused to the db mouse lost weight and eventually died of starvation9. 
Furthermore, when the ob and db animals were fused, the ob animal lost weight, while 
the db did not. Collectively, these experiments suggested that the ob mouse was lacking 
Kennedy’s circulating satiety factor, and that the db animal was lacking a receptor for a 
satiety factor. However, without a molecular mechanism to explain these observations, 
little advance could be made in understanding the basic organization of fat metabolism. 
The positional cloning of the ob gene in 1994 by Friedman and co workers 
ushered in a new era in which rapid progress could be made in unraveling the regulation 
of fat and energy homeostasis10. The Ob gene encodes a 167 amino acid protein, termed 
leptin (after the Greek “leptos” for thin), which, following processing of the signal 
sequence and secretion, circulates as a 146 amino acid protein of approximately 16 kDa. 
Several lines of evidence rapidly established that leptin could serve as Kennedy’s satiety 
factor: leptin is expressed in adipose tissue11,12, its expression is correlated with fat mass 
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in rodents and BMI in humans13, and treatment of the ob mouse with leptin rapidly 
corrects the obese phenotype14. Shortly thereafter, the leptin receptor (ObR) was cloned 
from a cDNA library from choroid plexus and was found to be contained within the db 
locus15. Subsequent studies demonstrated that ObR is expressed in the hypothalamus 
(among many other tissues)16, that leptin is transported into the brain by a saturable 
mechanism17, and that deletion of the gene in neurons was sufficient to generate an obese 
phenotype18. Thus, leptin is a circulating factor, produced by adipose tissue in proportion 
to lipid mass, which can signal the level of fat stores in the body and produce a 
compensatory response19. 
A human pedigree of individuals with an inactivating mutation in the leptin gene 
causing morbid obesity was described in 1997 by O’Rahilly and co-workers20, confirming 
that leptin is essential for normal energy homeostasis in humans. These individuals 
display a complex syndrome of obesity, hyperphagia, diabetes, central hypogonadism, 
abnormalities of T-cell number and function, hypothyroidism, and other endocrine 
abnormalities, which is corrected by replacement therapy with the hormone21. A similar 
syndrome is observed in individuals with loss of function mutations in ObR22. Several 
other genetic abnormalities of signaling downstream of leptin which cause morbid 
obesity have been described in humans, and these relatively rare occurrences have helped 
identify the roles played by these mediators in normal fat homeostasis23,24. 
Leptin’s mechanism of action suggested that it could function as an obesity drug. 
However, the weight loss induced by the hormone was less profound than expected, 
suggesting that obese humans were resistant to its actions25. The mechanism of leptin 
resistance in humans remains unclear, but it is likely that several factors play a role. 
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Obese humans have high circulating levels of leptin, but the high peripheral level is not 
necessarily reflected in the CNS, where the crucial hypothalamic leptin receptors are 
located26. Thus, transport of leptin into the brain may be reduced in obese individuals. 
Central leptin resistance may also play a role, as leptin signaling in the CNS also appears 
to be attenuated in various models of obesity27. Additionally, signaling pathways in 
neural or peripheral tissues downstream of leptin may be affected.  
The mechanism of leptin resistance in humans remains cryptic, but recently 
described combination therapies with the peptide amylin are promising for the treatment 
of obesity28,29. Additionally, leptin is used in the clinic for treatment of the fat deficiency 
seen in lipodistrophy, and may potentially be used for hypothalamic amenorrhea30,31. 
Further understanding of leptin physiology and resistance may help in the development of 
novel therapeutics. Thus, a more thorough characterization of the physiology of leptin 
production, biodistribution, and function is of central importance to the understanding of 
fat homeostasis and obesity in modern man. 
 
1.2 Leptin and Leptin Receptors (ObR) 
 Leptin circulates in mice and humans as a 146 amino acid protein of 
approximately 16 kDa32. The crystal structure of leptin revealed that it is a four-helix 
bundle with structural homology to long chain cytokines such as LIF, IL-6, and hGH 
(Figure 1)33. The lone post-translational modification is a disulfide bond between C96 and 
C146. Although no high-resolution structure of leptin receptor has yet been reported, its 
extracellular domain is a class I cytokine receptor, with sequence homology to the 
extracellular gp130 subunits of the IL-6, G-CSF, and LIF receptors. The extracellular 
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portion of leptin receptor is common to all isoforms, and consists of two cytokine 
receptor homologous domains (CRH1), an IgD like domain, and two fibronectin type III 
domains (Figure 2). Based on extensive mutagenesis and homology modeling, Peelman 
et al. have proposed a plausible model of leptin binding to leptin receptor in which 
signaling is activated in a 2:4 leptin:leptin receptor complex34. However, not all evidence 
supports this model35, and in the absence of further structural information the true 
mechanism of leptin:leptin receptor binding will remain obscure. 
 
 
Figure 1. The crystal structure of leptin. The disulfide bond between C96 and C146 is 
indicated in blue. The protein is a four helix bundle with homology to other cytokines 




 Leptin receptor is expressed as several different isoforms, with varying 
transmembrane and intracellular domains (Figure 2). By far the best characterized is 
ObRb, which is the longest of the isoforms, and is abundantly expressed in the 
hypothalamus. Abnormal splicing of the intracellular domain, causing a functional 
replacement of ObRa for ObRb, is the mutation underlying the obesity seen in the db 
mouse16. ObRb has a juxtamembrane segment which binds the JAK2 kinase, and two 
tyrosine residues (985 and 1138) which can be phosphorylated by this kinase (Figure 2). 
ObRb also activates STAT3, MAPK, PI3K, and AMPK downstream of JAK236. The 
short isoforms, ObRa, ObRc, ObRd, and ObRf, lack the full signaling capacity of this 
receptor37,38. ObRa and ObRc are highly expressed in choroid plexus and cerebral 
microvessels, suggesting that they may function in transporting leptin into the CNS, 
although this has not been proven39,40. ObRe lacks a transmembrane domain altogether, 
and circulates in the bloodstream where it binds to leptin, possibly modulating the half 





Figure 2. Simplified diagram of leptin receptor, long isoform (ObRb). Leptin binding to 
the IgD and CHR2 domains of the extracellular portion of the receptor drives recruitment 
of JAK2 to the juxtamembrane segment of the receptor. JAK2 then trans-phosphorylates 
the JAK2 associated with another receptor subunit, as well as STAT3, SHP-2, and other 
substrates. Engagement of the receptor by leptin drives gene transcription and repression 
via STAT3 and also activates MAPK, PI3K, and AMPK pathways. The figure represents 
full length ObRb, while ObRa, c, d and f lack the intracellular domain (with the exception 
of the JAK2 juxtamembrane binding segment), and ObRe lacks both the transmembrane 
and intracellular regions. 
 
 A variety of other non-ObR leptin-binding proteins have been described. For 
example, leptin binds to siglec-6, a sialic acid binding lectin abundantly expressed on the 
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placenta44. Additionally, leptin may bind to and be inactivated by C-reactive protein 
(CRP)45, although the results and conclusions of this study are controversial46-48. Leptin 
also binds to α-2 macroglobulin, an abundant serum protein, with an apparent affinity of 
2 μM49. Finally, leptin binds to megalin, a receptor abundantly expressed on kidney 
tubules50. Remarkably, the physiological significance of these binding partners, as well as 
most of the isoforms of the leptin receptor, remains unknown. 
 
1.3 Leptin action and binding in the CNS and in the periphery 
 Several lines of evidence support the concept that leptin signaling in the CNS is 
both required and sufficient to produce many of leptin’s effects51. Firstly, an ObR gene 
deletion in neurons in mice was sufficient to produce a syndrome nearly identical to that 
of total leptin receptor deficiency18. Secondly, the reintroduction of ObRb in neurons 
rescues the obese phenotype seen in db mice.52 Thirdly, direct injection of leptin into the 
CNS is much more potent at inducing its effects than peripheral injection53. Fourthly, 
lesions of the hypothalamus are sufficient to produce syndromes of hyperphagia and 
obesity54. Finally, many leptin resistant animal models have defective leptin signaling in 
the hypothalamus27. 
 There are two well-characterized populations of leptin-responsive neurons in the 
arcuate nucleus of the hypothalamus. The first produces two potent orexigenic peptides, 
agouti-related peptide (AgRP) and neuropeptide Y (NPY). These AgRP neurons are 
inhibited by leptin, and ablation of this population causes life threatening hypophagia55. 
The other population of neurons, which produce pro-opiomelanocortin (POMC), is 
activated by leptin. POMC is cleaved by proteases to generate a variety of peptides 
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termed melanocortins56. These POMC-derived melanocortins are agonists for 
melanocortin G-protein coupled receptors (principally MC3R and MC4R in the CNS), 
while AgRP is an antagonist at these receptors57. The AgRP and POMC neurons project 
to neurons expressing MC3R and MC4R in the lateral hypothalamus and paraventricular 
nucleus, which in turn produce a variety of downstream mediators of leptin action. Thus, 
leptin acts simultaneously on two populations of neurons, activating AgRP neurons, 
while inhibiting POMC neurons. The net effect of this program is to activate the central 
melanocortin signaling system, which causes anorexia and energy expenditure19,56,58. 
 While the direct action of leptin on the CNS is clearly required for its 
physiological outputs, strong evidence for direct peripheral actions of leptin has also 
accumulated (fig 3). ObRb mRNA is transcribed in several peripheral tissues, including 
pancreas59, lung37, kidney37,60, placenta61, adrenal glands60, T lymphocytes62, hematopoietic 
stem cells63, endothelial cells64,  fat65, and bone65. Furthermore, leptin administration in 
rats induces STAT3 phosphorylation in fat, muscle, and liver66. However, these data must 
be approached with caution as they do not exclude an indirect effect through the CNS, 
acting through similar downstream signaling mediators. Nevertheless, the presence of 
leptin receptor RNA, coupled with evidence of activation of signaling downstream of this 




Figure 3. A simplified summary of peripheral and central actions of leptin. 
 
The specific physiological effects of leptin on peripheral tissues have also been 
investigated (Figure 3). A tissue specific gene deletion of leptin receptor in the pancreas 
resulted in enhanced early phase insulin secretion, which was attenuated by high fat diet, 
suggesting that leptin modulates islet β-cell function67. Leptin also has direct effects on 
immune cells in vitro: it shifts T-cells towards a Th1 phenotype62 and stimulates T-cell 
proliferation68. Ob mice are resistant to the development of autoimmune disease69, and 
have defective cell mediated immune systems62, suggesting that leptin plays a permissive 
role in regulating the immune system in vivo. Furthermore, leptin, acting in concert with 
parathyroid hormone, may stimulate fetal lung to produce surfactant70. In adipose tissue, 
leptin may signal in a paracrine manner, which is suppressed in leptin resistant diet 
 11 
induced obese mice71,72. The physiological function of leptin signaling in adipose tissue is 
not yet understood, but may include increased lipolysis and glucose utilization73. In the 
placenta, which is itself a source of leptin, the hormone induces the release of pro-
inflammatory cytokines74. In muscle, leptin stimulates the phosphorylation of AMPK, 
increasing fatty acid oxidation, an effect that may be mediated in part by direct action on 
the muscle tissue75. Leptin may also act as an angiogenic factor in vivo by directly 
activating the proliferation of endothelial cells64. Thus, it is clear that in addition to the 
well established role of leptin in regulating food intake and energy expenditure in the 
hypothalamus, the hormone also directly modulates the physiology of peripheral organs. 
Collectively, leptin appears to signal the nutritional and energy status of the organism to 
peripheral tissues. A reduction of leptin, such as would be seen during starvation, alters 
the function of peripheral organs so as to conserve energy, and downregulates non-
essential functions. 
The binding of leptin to sites in the CNS and in the periphery has also been 
studied extensively. In this analysis, animals are sacrificed, and tissue sections are 
prepared. Radiolabeled leptin can then be bound to the sections, and visualized using 
autoradiography. Due to the fixation process, this analysis allows for visualization of both 
extracellular and intracellular leptin receptors. The initial cloning of leptin receptor was 
accomplished following autoradiographic localization of leptin binding in the choroid 
plexus, and subsequent expression cloning from a choroid plexus cDNA library15. This 
binding pattern was subsequently replicated by several other groups76-78. In the brain, 
leptin binds to various nuclei in the hypothalamus, including the arcuate, paraventricular, 
and ventromedial nuclei79,80. High affinity binding sites in the medulla of the kidney have 
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also been identified81. Leptin binding sites were also identified in the adrenal medulla82. 
In a particularly thorough study, Dal Farra et al. characterized leptin binding sites in mice 
at several stages of development83. Binding was found in the lung, digestive tract, liver, 
kidney, cartilage, spleen, and in the choroid plexus. Taken together, these experiments 
show that leptin binds to ObR in peripheral and central tissues, where it activates 
signaling, producing a diversity of outputs to regulate energy homeostasis, as well as to 
conserve energy in times of starvation. 
 
1.4 The application biodistribution studies to leptin 
 One approach to integrate the enormous amount of data on the divergent functions 
of leptin would be to study the biodistribution of the hormone in live animals. This 
methodology could confirm the validity of studies of leptin activity and ex vivo binding 
in various peripheral or central tissues, as well as discovering new functions of the 
hormone in an unbiased approach. Additionally, specific hypotheses about the molecular 
identity of leptin binding partners or transporters could be assessed using appropriate 
animal models.  
Before the development of high resolution in vivo imaging technology, the 
method traditionally used to assess these parameters was biodistribution analysis. In this 
technique, a radiolabeled tracer is injected into an animal, and after a predetermined 
period of time, the animal is sacrificed, and the radioactivity in various tissues counted. 
These data complement tissue binding and mRNA expression data (section 1.3), as they 
account for a physiological pattern of cell surface receptor expression. By far the most 
commonly used tracer for this purpose is 125I-leptin. 125I-leptin has been used for the 
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purpose of studying leptin half-life and clearance in mice, rats, and rhesus monkeys. The 
half-life of leptin has been found to follow bi-exponential decay, which presumably 
represents rapidly cleared free leptin, and more slowly cleared leptin bound to circulating 
receptors (mainly ObRe). The first phase half-life is very fast, under 10 minutes in rats, 
while the second phase is about one hour84-86. These and other studies also revealed that 
leptin was cleared from the circulation by the kidney, as expected for small 
polypeptides50,87-90. This is consistent with the fact that human patients with end-stage 
renal disease have relative hyperleptinemia when the values are corrected for their BMI91. 
In addition to binding in the kidney and choroid plexus, one study also suggested that 
leptin was taken up in the bone marrow in mice92.  
Leptin transport into the CNS has also been extensively studied using 
biodistribution methodology. A saturable, low capacity transport system into the CNS has 
been defined in cerebral microvessels by using 125I leptin17. However, the transporter 
responsible for this phenomenon has not yet been identified. While ObRa is abundantly 
expressed at the capillary endothelium and choroid plexus78, and is able to transcytose 
leptin in cell lines93, isolated brain preparations from rats lacking ObR have identical 
transport rates compared to normal rats and mice40,94 . Thus, the commonly cited 
observation that mice and rats lacking ObR have reduced transport of leptin into the brain 
is likely an artifact of the compensatory high levels of leptin in these animals39,95. The 
identity of this molecular transporter is crucial to understanding leptin resistance, as 
reduced transport of leptin into the CNS has been proposed to underlie leptin resistance 
seen in obese humans26. 
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1.5 In vivo imaging methodologies and application to leptin 
 A live animal imaging approach has advantages over the classical biodistribution 
approach in studying leptin biology. In particular, quantitative kinetic information of 
uptake in various organs can be readily obtained, and probes can be readily translated 
into studies in nonhuman primates and into the clinic. To date there have been two live 
animal imaging studies of leptin biodistribution, in different contexts. Karonen et al. 
studied the biodistribution of 123I labeled leptin in rabbits using dynamic gamma 
imaging96. In this study, the authors saw uptake in the lungs, kidney, liver, and choroid 
plexus. However, the relatively low resolution of the images makes the conclusions 
difficult to verify and interpret. McCarthy et al. labeled leptin with the positron emitting 
isotope 68Ga using the chelator diethylene triamine pentaacetic acid (DTPA)97. They 
subsequently imaged the biodistribution of leptin when injected into the intrathecal space 
in baboons using positron emission tomography (PET). In this study the authors found 
that the intrathecally injected leptin moved rostrally to the cranium, but that there was 
considerable variation in the three animals tested. Thus, to date there has been no 
comprehensive study of leptin biodistribution using in vivo imaging technologies. 
Several live animal imaging approaches could be used to study leptin biology. In 
principle, fluorescence, bioluminescence, magnetic resonance imaging (MRI), and 
positron emission tomography (PET) could readily be applied to studying leptin biology. 
For example, a fluorescently labeled leptin derivative could be imaged in vivo or a leptin 
derivative labeled with gadolinium could be imaged using MRI. However, in comparing 
the available imaging technologies for this purpose, positron emission tomography (PET) 
has several advantages (table 1)98. It has the highest sensitivity of currently available 
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imaging techniques, while still retaining excellent spatial resolution, and ease of 
quantification. Additionally, PET can be readily translated into large animal systems and 
into the clinic. Thus, we chose to study leptin biodistribution using PET. 
 
Imaging modality Form of energy 
Spatial 
resolution Sensitivity Quantification Organism 
Fluorescence Visible/NIR 2-10 mm +++ low mouse 
Magnetic 














Table 1.  A comparison of live animal imaging techniques. Adapted from Levin, C.S., 
Eur. J. Nucl Med. Mol. Imaging98. 
 
1.6 Technical aspects of PET tracer development: Isotopes, labeling chemistries 
 Positron emission tomography requires that the tracer of interest be labeled with a 
positron emitting isotope. Positron emitting isotopes, such as 18F or 64Cu, are intrinsically 
unstable and decay, producing positrons, which travel a short distance in tissue before 
finding their antiparticle, the electron. When positron/electron pair collide, they 
annihilate, producing two antiparallel photons of 511 keV. These photons are 
subsequently counted by a detector. Following various corrections to account for 
scattering effects, an image can be reconstructed with excellent spatial resolution (in the 
1-2 mm range). Careful design of a tracer is crucial to obtaining high-resolution images 
that correspond to the authentic biodistribution99. 
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 Probably the single most important decision regarding PET tracer development is 
isotope selection. An variety of isotopes are currently available (table 2) with differing 
properties100. The half-life of an isotope is an important parameter, as in practice any 
labeling technique which cannot be accomplished in 3 half-lives of the isotope is unlikely 
to be successful. Thus, very short -lived isotopes such as 15O and 13N are not used 
frequently. A second important feature is the percentage of positrons emitted by an 
isotope: other modes of decay can confound the imaging results and produce undesirable 
radiation exposure. Additionally, the energy of the positron emitted (Bmax) limits the 
resolution of the image obtained, as high energy positrons undergo various scattering 
events prior to annhilation101. The final factor regarding isotope selection is the method of 
generation, either via cyclotron, generator, or reactor. Cyclotrons are relatively common 
in nuclear medicine, radiology, and oncology departments due to the popularity of 18F -
fluorodeoxyglucose (FDG), the most commonly used PET tracer. Nuclear reactors will 
remain rare due to safety considerations. A generator is a smaller device containing a 
fixed amount of a parent isotope, which decays continually, to a positron emitting isotope 
of shorter half-life. Thus, the generator produces a constant supply of a desired isotope, 
which can be used approximately every 3-4 half-lives. Based on the considerations of 
half -life, resolution, and method of production, 18F has emerged as the leading isotope 
for PET, with 11C being nearly as widely used for small molecule tracers. Other isotopes 
are more commonly used for specialized applications- for example radiometals are 














11C 20.5 min 0.96 100 cyclotron 
13N 9.97 min 1.2 100 cyclotron 
15O 122.2 sec 1.73 100 cyclotron 
18F 109.8 min 0.63 99 cyclotron 
64Cu 12.8 hours 0.65 18 cyclotron 
68Ga 68.3 min 1.92 89 generator 
76Br 15.9 hours 3.94 54 cyclotron 
86Y 14.7 hours 3.14 34 cyclotron 
124I 4.17 days 2.14 23 cyclotron 
Table 2. Commonly used positron emitting isotopes. 
 
 PET radiochemistry is fundamentally similar to organic/inorganic chemistry, but 
has several key differences. Firstly, owing to the short half-life of the isotopes, the 
labeling must be performed rapidly. Secondly, the reactions must be performed at trace or 
“no-carrier added” level: 10 MBq of 18F, a typical dose injected into a mouse in a PET 
experiment, is only 200 fmol of the isotope. Thus, in practice not all reactions are 
applicable to PET radiolabeling. Finally, positrons produce highly energetic, penetrating 
gamma rays, which for safety reasons require extensive shielding and precautions.  
 The generation of a high quality PET tracer requires that several design 
considerations be observed. Firstly, the tracer itself must be chemically and biologically 
similar to the normal, unmodified molecule which it is attempting to mimic. Frequently, 
for small molecular tracers, it is possible to generate a tracer with no changes made to the 
intact structure of the molecule. However, this is not always possible, and the case of 
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peptide and protein labeling, nonnative prosthetic reactive groups must be installed103. 
Therefore, it is crucial to test if a modified tracer retains its biological activity. This is 
generally accomplished by generating a “cold” version of the molecule in which the 
positron-emitting isotope is replaced with the naturally occurring one, and testing its 
activity in various biological assays. Finally, the specific activity (defined as the amount 
of radioactivity in Curies or Becquerels per mole) determines which interactions can be 
visualized. If the tracer has low specific activity, a large molar amount of tracer must be 
used to enable visualization, potentially saturating the binding sites which are to be 
studied104. However, with careful selection of isotope, labeling site, conjugation 
chemistry, and technique, high quality, high specific activity positron emitting tracers 
can, in principle, be generated with biological activity intact. 
 
1.7 Chemical and radiochemical aspects of protein labeling for PET imaging 
 Proteins are both particularly desirable and challenging targets for labeling with 
positron emitting isotopes. The challenge of labeling them arises from the fact that there 
is no generally applicable method for radio-conjugation without destroying their activity, 
and that since they generally produce their effect in vivo with high affinity (typically low 
nanomolar), the labeled tracer must have very high specific activity. Furthermore, 
proteins can not generally be exposed to extreme conditions, such as high temperature, 
microwave heating, or treatment with organic solvents since these will denature them. 
Thus, protein labeling with positron emitting isotopes is generally accomplished with 
robust reactions which can proceed at lower temperatures. 
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 The most commonly used technique for labeling proteins with positron emitting 
isotopes is the chelation of radiometals, such as 68Ga and 64Cu102,105. This can be 
accomplished by appending a chelator to the protein and subsequently complexing the 
modified protein with the radiometal of interest. By far the most commonly used chelator 
for this purpose is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)106. A 
wide variety of metals, such as the postiron emitting 64Cu or 68Ga, can be incorporated, 
and the metal complexes formed with this chelator are stable over the course of days in 
live animals. Furthermore, DOTA derivatives for labeling lysine and cysteine side chains 
are commercially available. Thus, DOTA, and other metal chelators such as diethylene 
triamine pentaacetic acid (DTPA) are widely used for protein labeling with positron 
emitting isotopes. 
 Radiohalogens are the second most frequently used nuclides for postiron emitting 
isotope labeling of proteins. 124I, 75Br, 76Br, and 18F are all positron emitters with useful 
half lives.  Iodine and bromine isotopes can be installed using conventional 
radiohalogenation chemistry, for example using Chloramine-T, Iodogen, or enzymatic 
peroxidases107. However, the low percentage of positrons emitted and high energy of 
those positrons emitted by these isotopes (table 2) results in low quality images in a 
micro-PET setting. Owing to the favorable imaging properties of the isotope, 18F labeling 
of peptides and proteins is particularly desirable. However, standard radiohalogenation 
chemistry is not applicable, as synthesis of 18F-F2 can only be accomplished in the 
presence of carrier, resulting in very low specific activity. Nucleophilic 18F- is highly 
unreactive in water due to solvation, and thus cannot be directly installed on proteins via 
currently available techniques. Recently, promising methods for one step labeling of 
 20 
small molecules and peptides have been developed based on the incorporation of boronic 
acids or organosilicon, and treatment with fluoride anion in organic solvents108,109. At 
present, these techniques are not applicable to protein labeling due to the requirement for 
organic solvents109, or very high concentrations of the reactive precursor108. Thus, 18F is 
currently conjugated to proteins using multistep reactions, in which 18F is first introduced 
into an organic reactive group which is subsequently conjugated to the protein of 
interest110,111. Due to the optimal imaging properties of 18F these labeling methodologies 
are an area of intense interest in the field of radiochemistry. The currently available 
techniques for peptide and protein radiofluorination, as well as our own developments in 
this area will be covered in chapter 2.  
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Chapter 2. Design, synthesis and characterization of 18F and 68Ga labeled leptin 
tracers 
 
2.1 Labeling of proteins for PET and design considerations for isotopic labeling of 
leptin 
PET has emerged as a powerful tool for in vivo imaging in clinical medicine as 
well as in basic research.  PET imaging is complementary to other in vivo imaging 
techniques such as single photon emission computed tomography (SPECT), fluorescence 
imaging, bioluminescence imaging, and magnetic resonance imaging (MRI), and in 
particular it offers good resolution, high sensitivity, ready translation to clinical studies, 
and ease of quantification98,99,112. PET requires that a probe of interest be labeled with a 
positron emitting nuclide, such as 18F, 11C, or 68Ga100. 18F is a particularly desirable 
radionuclide for PET imaging owing to its intermediate half-life of 109.7 minutes, its 
routine availability by biomedical cyclotron production, and the high resolution of images 
obtained.  Proteins and peptides are widely used tracers in PET and a variety of 
techniques, principally based on the incorporation of radiometals, have been developed to 
label them102. The interest in peptide imaging and the superior imaging properties of 18F 
has led to the development of several approaches for labeling synthetic peptides with this 
isotope109-111,113-121. Protein labeling using 18F synthons targeting lysine122-125 residues has 
also been developed and applied to a variety of substrates. However, in contrast to the 
aforementioned peptide labeling approaches, these protein labeling techniques give rise 
to a variety of labeled products, and it is difficult to characterize the structure or function 
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of the tracer. Site-specific labeling of proteins is particularly desirable as it allows 
unambiguous biophysical and activity-based characterization of a homogeneous product, 
leading to reproducibility in labeling and imaging126,127. Accordingly, the generation of 
site-specifically labeled proteins for molecular imaging has become an area of active 
research126. Recently, site-specific 18F labeling of proteins on unique cysteine residues has 
also been described128-132. These site-specifically radiolabeled proteins are promising 
reagents for molecular imaging for biodistribution studies in model animals as well as in 
the clinic. 
In order to study leptin biodistribution using PET, we developed two 
complementary labeled tracers, which we term 18F-FBA-leptin and 68Ga-DOTA-leptin. 
While no high resolution crystal structure of a leptin-leptin receptor complex has been 
reported, mutagenesis studies have established the residues of leptin which are required 
for both receptor binding and activation34,133,134. The lysine residues of the protein, and 
both the C and N termini of the molecule, are mainly distributed elsewhere on the 
structure from the receptor binding region33,135. We therefore rationalized that either an 
amine-directed or a site-specific C-terminal labeling strategy would produce a labeled 
leptin derivative with unaltered bioactivity (Figure 4).  Thus, we have developed an 
amine-directed labeling method for 68Ga labeling using the chelator DOTA, and a site-







Fig 4. Design, synthesis, and biological activity of the tracers 18F-FBA-leptin and 68Ga-
DOTA-leptin. Two views of the structure of leptin (PDBID 1AX8), with side chains 
rendered as spheres for residues which are known to be required for ObR binding 
(yellow). The potential labeling sites for 68Ga-DOTA-leptin (lysine side chains and the N-
terminus) are rendered as red spheres, while the C-terminus, the labeling site of 18F-FBA-
leptin, is rendered as a blue sphere. 
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2.2 Development of 68Ga-DOTA-leptin 
 Radiometallation of proteins is a widely used technique in radiochemistry, with 
68Ga and 64Cu being the most commonly used postiron emitting isotopes for labeling102. 
68Ga is obtained from a 68Ge generator, making it an attractive method for labeling. 68Ga 
labeling of a protein was first reported in 1975 with an albumin labeling strategy136, and 
the key findings of this study remain the crucial guidelines for 68Ga labeling today - 68Ga 
labeling is optimal at acidic pH (2.5-4.5) due to the formation of insoluble Ga(OH)3 
complexes at higher pH, and must be accomplished rapidly due to the short 68 minute 
half life. The development of the high affinity chelators diethylene triamine pentaacetic 
acid (DTPA) and 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 
allowed more practical and extensive use of this isotope, owing to the inertness and 
stability of the chelated metal complexes106,137,138. DOTA chelates gallium via a 
hexadentate interaction in which the metal is coordinated axially by two nitrogens and 
two opposite carboxylates, and equatorially by the remaining two nitrogens139. Recently 
68Ga-DOTA labeled peptides have become popular for use in PET and biodistribution 
studies, and are promising reagents for use in clinical diagnosis104,140-143. 
Thus, in order to study leptin biodistribution, we developed a lysine directed 
labeling approach to conjugate the isotope 68Ga to leptin using the metal chelator DOTA 
(Figure 7a). Using DOTA-NHS, we found that the level of labeling of the protein could 
be controlled by varying the molar excess of DOTA-NHS used in the reaction (Figure 5). 
Out of eight possible labeling sites (seven lysines plus the N-terminus), we found that we 
could conjugate and average of one to four copies of DOTA to leptin by varying the 
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reaction conditions. In preliminary studies, we found that radiolabeling was most 
efficient using the most heavily modified tracer (data not shown). Thus, we pursued this 
compound, with an average of four copies of DOTA per leptin molecule (figure 7b) for 





Figure 5. ESI-MS reconstructs of DOTA-NHS : Leptin conjugation reactions. All 
reactions were performed at pH 7.5, 5 mg/mL leptin, with the indicated number of 




In order to verify the bioactivity of our DOTA-modified protein, its activity was 
tested in several assays. A cell-based assay was developed using a 293 cell line stably 
transfected with ObRb, and luciferase under the control of a STAT3-dependant element 
(Figure 6). As expected based on the design considerations (Figure 4), the ability of the 
modified protein to activate leptin receptor STAT3-dependant signaling was unaltered in 
this cell line (Figure 7c). Additionally, the ability of DOTA-leptin to induce weight loss 
in leptin deficient (Ob/Ob) mice was identical to unmodified recombinant leptin over a 
period of 9 days, when administered via subcutaneous osmotic pumps (Figure 7d).  Thus, 
labeling leptin with DOTA using an amine directed labeling strategy does not alter its 
bioactivity. 
Radiolabeling of the protein using 68Ga proceeded in good yield (decay corrected 
yield of 25.7% ± 4.9% s.d., n = 30, specific activity of 5.5 – 11 GBq/μmol, scheme 1), 
affording a product that was always greater than 90% pure (Figure 7e). As expected 
based on the extraordinary inertness of DOTA-metal complexes, the tracer was stable in 
vivo as assessed by HPLC analysis of the serum recovered from a mouse injected with 
68Ga-DOTA-leptin 30’ prior (Figure 7e). Finally, the 68Ga labeling procedure did not 
abrogate receptor-binding activity, as the labeled protein bound to the aforementioned 
cell line expressing ObR, and the binding could be displaced by excess competing cold 
leptin (Figure 7f). Thus, leptin can be labeled with 68Ga, preserving the biological activity 




Figure 6. Schematic of ObRb-STAT3-Luciferase assay. A 293 cell line is stably 
transfected with ObRb and luciferase under the control of a STAT3 dependant element. 
In this cell line, leptin binds to and activates ObRb, which recruits JAK2 to the receptor. 
Phosphorylated leptin receptor subsequently recruits STAT3, which is phosphorylated by 
receptor-bound JAK2. Phosphorylated STAT3 dissociates from the receptor, translocates 
to the nucleus, where it activates luciferase gene transcription. Luciferase activity can 
then be quantified using a luminometer. Thus, luciferase is produced in a leptin dose-
dependant manner.   
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Figure 7. a) Schematic of 68Ga-DOTA-leptin tracer. b) ESI-MS of DOTA-leptin 
revealing an average of 4 copies of DOTA per leptin molecule. c) in vitro bioactivity of 
DOTA-leptin was compared to recombinant leptin using a 293 cell line stably expressing 
leptin receptor (ObRb) and a luciferase reporter under STAT3 responsive element. The 
EC50 for activation was 0.42 to 0.55 nM for recombinant leptin and 0.54 to 0.66 nM (95% 
confidence intervals, n=2 ± s.d.) for DOTA-leptin. d) DOTA-leptin induces weight loss 
to a similar extent as recombinant leptin in ob/ob mice (n=4 ± s.e.m., dose = 450 ng/hr). 
e) Radiochemical HPLC analysis of purified 68Ga-DOTA-leptin (blue) and serum 
recovered from a mouse 30 minutes post injection with 68Ga-DOTA-leptin, demonstrating 
the stability of the tracer in vivo. f) Cell binding assay of 68Ga-DOTA-leptin using a 293 
cell line overexpressing ObRb, in the presence or absence of 1 μM competing 





Scheme 1. Schematic of method used to label DOTA-leptin with 68Ga. 
 
 
2.3. Development of expressed protein ligation to site-specifically label the C-
terminus of leptin 
 In designing a site-specific leptin 18F labeling protocol, various options were 
considered. While in principle a cysteine directed labeling approach could produce site 
specifically 18F labeled leptin, we found that the introduction of additional cysteines in 
the protein led to difficulties in refolding and protein purification (data not shown). 
Fortunately, the C-terminal amino acid of leptin is cysteine, which in principle would 
allow for direct modification of the protein using expressed protein ligation (EPL)144. 













































































ligation, in which a recombinantly expressed protein α-thioester is fused to any peptide 
containing an N-terminal cysteine. In native chemical ligation, an unprotected peptide 
with an N-terminal cysteine can react with a second peptide with a C-terminal α-thioester 
to form a peptide bond (Figure 8a)145,146. The fusion of a recombinant protein α-thioester 
with a synthetic N-terminal cysteine peptide was accomplished by re-engineering the 
process of protein splicing. In protein splicing, a protein segment termed an intein is 
excised out of two flanking sequences, named exteins, in a process analogous to the 
splicing of RNA introns (Figure 8b)147. This fascinating autocatalytic process has been 
exploited for many different purposes by our group and others. However, one of the 
simplest uses of protein splicing has proven to be the most versatile: by mutating the 
intein to prevent the formation or breakdown of the branched intermediate, the protein 
can be trapped in equilibrium between the α-thioester and amide forms. The mutated 
intein can then be cleaved by treatment with thiols, generating a recombinant protein α-
thioester. The ligation of the recombinant protein α-thioester with a synthetic N-terminal 
cysteine peptide was first reported in 1998 (Figure 8c)148-150, and has been termed 




Figure 8. Mechanism of native chemical ligation (NCL) (a). In NCL, trans-
thioesterification by the N-terminal cysteine is followed by an S->N acyl shift, generating 
a native peptide bond. Mechanism of protein splicing (b). In protein splicing, an N -> S 
or O acyl shift at the N-terminal residue of the intein is followed by trans(thio)-
esterification to the residue C-terminal to the intein, generating a branched intermediate. 
The C-terminal Asn of the intein then cleaves the C-terminal intein-extein bond, 
generating a succinimide product, and the fused exteins undergo an (S,O)-> N acyl shift 
to create a native peptide bond. Mechanism of EPL (c). In EPL, a thiol is used to generate 
a α-thioester from a mutated intein. The α-thioester can then react by NCL with an N-
terminal cysteine peptide. R = alkyl, phenyl, benzyl, CH2CH2SO3Na. X = O, S. 
 
 
 Heterologous expression of leptin in E. coli generally requires isolation from 
inclusion bodies151.  Thus, in order to generate an active intein fusion protein, we fused 
leptin to the GyrA intein, which can be refolded from bacterial inclusion bodies using 
conditions previously developed in our laboratory152. Unfortunately, these refolding 
conditions resulted in precipitation of the leptin-GyrA fusion. Thus, we tested the ability 
of the intein to cleave in the presence of various additives, including detergents, small 
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molecule additives, and chaotropes. We found that 4M urea was most effective in 
promoting the cleavage of the intein (Figure 9). Upon refolding in 4M urea, intein 
cleavage with sodium-2-mercaptoethanesulfonate allowed the preparation of the 
corresponding α-thioester (Figure 10).  Following EPL of the α-thioester with cysteine to 
reconstitute full-length leptin (Figure 11a), and refolding to form the disulfide bond 
between Cys97 and Cys147 using reduced and oxidized glutathione as a redox couple, 
leptin with activity identical to recombinant commercial leptin could be produced (Figure 
11b). These optimized protocols were subsequently applied to the generation of a site 
specifically 18F labeled protein (see section 2.4). 
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Figure 9. Optimization of leptin intein-cleavage conditions. Leptin-GyrA-His6 was 
refolded into pH 7 buffer containing the indicated additives and cleaved with 3% 




Figure 10. A) Expression and purification of leptin α-thioester 1. Coomassie stained 4-
20% gradient SDS-PAGE analysis of leptin purification fractions. A: Crude insoluble 
fraction from cell lysate. B: Leptin-GyrA-His6 purified on a Ni-NTA column. C: 
Cleavage of leptin-GyrA-His6 using 100 mM MESNa. D: Eluate of leptin α-thioester 1 
from the Ni-NTA column, E: Purified leptin α-thioester 1. B) ESI-MS of leptin-MESNa 
α-thioester 1 (calculated mass 16156.2 Da, obtained 16157.2 ± 3.0 Da). Charge states are 




Figure 11. A) ESI-MS reconstruct of murine leptin produced in an EPL protocol 
(calculated mass 16135.6, obtained 16134.6 ± 2.5). B) Leptin receptor-STAT3 dependant 
luciferase assay comparing the activity of recombinant leptin produced by an EPL 
protocol and recombinant leptin obtained from a commercial source. EC50 for 
recombinant leptin = 0.49 nM (95% confidence intervals 0.39-0.61 nM). EC50 for 
semisynthetic leptin = 0.31 nM (95% confidence intervals 0.25-0.38 nM) 
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2.4 Synthesis of 18F-FBA-leptin 
As mentioned above (see section 1.7, 2.1), several methods for protein labeling 
with the isotope 18F have been described. While a one step radiochemical labeling 
strategy, in which aqueous 18F could be directly appended to leptin, would be optimal, 
current methods are not applicable to protein labeling due to the very low specific activity 
of the resulting products108, or the requirement for organic solvents109. Thus, a two-step 
methodology was required. We were attracted to the use of 18F-4-fluorobenzaldehyde 
(FBA), owing to its previous use in chemoselective ligations with synthetic peptides114. 
We rationalized that leptin could be radiolabeled using this synthon, if the protein were 
labeled site-specifically with an aminooxy functional group. Thus, we developed an EPL 
strategy for labeling leptin site-specifically at its C-terminus with an aminooxy functional 
group for the purpose of site-specific oximation with 18F-FBA. Again, this strategy 
exploits the fact that leptin has a cysteine at its N-terminus, allowing for the facile 
incorporation of modifications using EPL. 
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Scheme 2: Synthesis of 18F-FBA-leptin 5. Reaction conditions: a) 100 mM 
mercaptoethanesulfonic acid, 4M urea, 150 mM NaCl, 100 mM sodium phosphate pH 
7.0, 4 °C, 2 days. b) 20 mg/mL 1, 10 mg/mL 2, 100 mM mercaptoethanesulfonic acid, 
6M Gn-HCl, 150 mM NaCl, pH 7.2, 1 day. c) Refolding by stepwise dialysis and 
disulfide exchange. d) 20 mg kryptofix, 2 mg potassium carbonate, 1-2 mg (4-
formylphenyl)trimethylammonium trifluoromethanesulfonate and K18F in DMSO, 120 
°C, 8 minutes. e) 30 nmol 4, 100 mM anilinium acetate pH 4.5, 15 minutes, 0° C. 
 
 
An overview of the synthetic strategy to generate 18F-FBA-leptin is depicted on 
Scheme 2. Leptin α-thioester 1 was prepared as described in section 2.3 and ligated to 
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cysteine derivative 2 to give leptin analog 3 (Scheme 2). Compound 2 was synthesized by 
solid phase methods and contains two reactive moieties, namely a cysteine and an 
aminooxy group, separated by a short PEG spacer (Scheme 3, Figure 12). In preliminary 
studies, we found the PEG spacer was required to maintain native-like solubility of the 
final folded product. We anticipated that at pH 7 the α-thioester in protein 1 would react 
preferentially with the cysteinyl group in 2, via native chemical ligation, due to the 
relatively slow rates of hydroxymate formation under these conditions153,154. The EPL 
reaction between 1 and 2 was complete after 24 hours at which point the crude ligation 
mixture was refolded as described above. The refolded aminooxy-leptin analog 4 was 
then purified by RP-HPLC (Figure 13a, b). Aminooxy-leptin analog 4 gave an identical 
tryptic digestion pattern to commercially available recombinant leptin as determined by 
LCMS (Figure 13c). As expected for natively folded leptin, the two C-terminal tryptic 
peptides in 4 were found to be linked by a disulfide bond, while no reduced tryptic 
peptides could be found. Interestingly, the mass spectrum of this disulfide-linked C-
terminal tryptic peptide contained a peak of mass consistent with loss of aminooxy-
acetate.  The presence of this fragment, which may have been produced either by 
trypsinolysis of the aminooxyacetate, or by gas phase fragmentation, provides evidence 
that protein 4 contains the desired amide bond at the ligation site, since aminooxy-acetate 




Scheme 3. Solid phase synthesis of peptide 2. Reaction conditions: A) Standard Fmoc-
SPPS. B) 2% Hydrazine in DMF followed by 8 equivalents of Boc-aminooxyacetic acid 
activated with diisopropylcarbodiimide. C) 1% triisopropyl silane, 2.5% ethanedithiol, 





































































Figure 12. A) C18 analytical RP-HPLC chromatogram of purified peptide 2 on a 5-20% 





Figure 13. Synthesis and characterization of AOA-leptin 4. a) RP-HPLC chromatogram 
of 4 on a 0-100% B gradient on a C4 analytical column.  b) ESI-MS reconstruct of AOA-
leptin 4 (calculated mass 16652.2 Da, obtained 16652.2 ± 3.3 Da). c) Trypsinization 
HPLC/MS analysis of commercial recombinant leptin (black) and AOA leptin 4 (red). 
The indicated peaks connected by a line were identified as the corresponding tryptic 
peptides by ESI-MS. The disulfide bond between C97 and C147 is indicated. 
 43 
Cold FBA-leptin derivative 5 was generated by overnight treatment of 4 with 1 
mM 4-fluorobenzaldehyde at 4 °C in 100 mM sodium acetate buffer, pH 4.5. No side 
reactions were detected, and the resulting oxime-containing product was purified by RP-
HPLC and the identity confirmed by ESI-MS (Figure 14a). FBA-leptin 5 was then tested 
for its ability to activate leptin receptor signaling using the aforementioned ObRb-
STAT3-luciferase assay (Figure 6). In this assay, 5 induced leptin receptor signaling to a 
similar extent as commercial recombinant leptin, with a slightly increased EC50 (95% 
confidence intervals 0.26-0.34 nM for recombinant leptin and 1.0-2.0 nM for 5, Figure 
14b). This subtle reduction in potency observed for 5 was not due to the ligation or 
refolding procedures employed in its preparation as unmodified leptin generated via a 
similar EPL procedure had an identical EC50 compared to commercial recombinant leptin 
in this assay (Figure 11b). Importantly, when administered to ob/ob mice via 
subcutaneous osmotic pumps, FBA-leptin 5 had identical ability to induce weight loss 
over a 24 hour period as commercial recombinant leptin (Figure 14c). We conclude that 
FBA-leptin 5 is able to bind and activate the leptin receptor, and that it is able to induce 
weight loss in mice, the hallmark of leptin bioactivity. 
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Figure 14. Characterization and biological activity of FBA-leptin 5. a) ESI-MS 
reconstruct of FBA-leptin 5 (calculated MS 16758.3, obtained 16760.9 ± 3.5). b) ObR-
STAT3 dependant luciferase assay comparing the activity of FBA-leptin 5 (blue 
triangles) and recombinant leptin (red squares), n = 2 ± s.d.. c) Comparison of the weight 
loss induced by FBA-leptin 5, recombinant leptin, and PBS vehicle in ob/ob mice. 
Samples were infused at a constant rate of 450 ng/hr. The weight of the animals was 
recorded after 24 hours (n = 4 ± s.e.m). 
 
Synthesis of 18F-FBA was accomplished as previously described155, with minor 
modifications, using the precursor (4-formylphenyl)trimethylammonium 
trifluoromethanesulfonate. Initial attempts towards oximation of 18F-FBA with leptin 
analog 4 failed owing to precipitation of the protein at elevated temperatures required to 
allow the reaction to proceed in good yield114,115. Jencks and co-workers described 
catalysis of semicarbazone formation between 4-chlorobenzaldehyde and semicarbazide 
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by aniline and substituted derivatives thereof, and recently Dawson and co-workers found 
that aniline acts as a catalyst in peptide oxime ligations156,157. Thus, we reasoned that 
aniline should catalyze the radiochemical oximation of 18F-FBA with aminooxy-leptin 4. 
Comparison of the rate of oximation of aminooxy-leptin 4 in 100 mM sodium acetate or 
anilinium acetate at 4 °C revealed that aniline dramatically accelerates the reaction 
(Figure 15a). Notably, aniline catalysis allows the reaction to proceed in good yield at 
lower concentration of the aminooxy precursor, and at lower temperature than previously 





Figure 15. Catalysis of radiochemical oximation of AOA-leptin 4 with 18F-FBA by 
aniline and characterization of the 18F-FBA-leptin 5. a) Catalysis of the oximation 
reaction by aniline. 125 uM 4 was incubated with 18F-FBA in the presence of either 100 
mM sodium acetate pH 4.5 (triangles) or 100 mM anilinium acetate (diamonds) at pH 4.5 
on ice. The radiochemical yield was quantified by TLC and confirmed by RP-HPLC. The 
results are an average ± standard deviation of four experiments. b) Radiochemical HPLC 
of 18F-FBA-leptin 5, on a C4 analytical column. c) 18FBA-leptin 5 was incubated with a 
cell line overexpressing ObRb in the presence or absence of 5 μM competing leptin 




Scheme 4. Overview of method to label aminooxy-leptin 4 with 18F-FBA. 
 
 
The method for preparative-scale labeling of aminooxy-leptin 4 with 18F-FBA is 
depicted on Scheme 4. Preparative scale 18F labeling of aminooxy-leptin 4 was 
accomplished by treatment with 18F-FBA in 100 mM anilinium acetate on ice for 15 
minutes, and purification of the resulting mixture on a P-6 gel filtration column. Using 
this method, 74-185 MBq (2.5-5.0 mCi) of 18F-FBA-leptin 5 could be recovered starting 
from 7.4-11.1 GBq of 18F, with a total synthesis time of ~120 minutes (n=4). The specific 
activity of the protein varied from 9.25-16.65 GBq/μmol, and the radiochemical purity of 




























































of 18F-FBA-leptin 5 to bind to the aforementioned cell line expressing ObRb was tested. 
We found that the labeled protein bound to the cells when incubated together at room 
temperature, and that binding could be blocked by the addition of an excess of 
unmodified recombinant leptin (Figure 15c). Additionally, the presence of the toxic 
catalyst aniline could not be detected in the final preparation of leptin by RP-HPLC.  
The stability of the 18F-FBA-leptin 5 was tested both in vitro and in vivo. Over the 
course of an hour, the protein was stable in PBS (10 mM sodium phosphate, 140 mM 
sodium chloride, pH 7.4), 100 mM sodium acetate, pH 4.5, and mouse serum in vitro as 
determined by HPLC analysis (Figure 16b-d). Finally, the stability was tested in vivo. In 
blood recovered from mice, greater than 95% of the radioactivity detected corresponded 
to intact 18F-FBA-leptin 5 (Figure 16a). Thus, the stability of the protein is sufficient for 
studies both in vitro and in vivo. Importantly, this synthesis provides sufficient highly 
stable radiolabeled protein in good specific activity for studies in small and large animals, 





Figure 16. Stability of 18F-FBA-leptin 5 in vivo and in various buffers. a) Radiochemical 
RP-HPLC of serum recovered from wild type mice injected with 18F-FBA-leptin 5 30 
minutes prior. Similar results were obtained from ob/ob mice. b-d) Radiochemical HPLC 
of 18F-FBA-leptin after incubation for 60 minutes in PBS, 100 mM sodium acetate pH 
4.5, or mouse serum, respectively. Stability in PBS and sodium acetate was greater than 
95% while in serum it was 93% stable. The initial purity of the labeled product in this 
experiment was 96%. 
 
 
We next performed preliminary PET imaging experiments in mice. 18F-FBA-
leptin 5 (3.7-5.55 MBq) was injected in ob/ob mice, and they were immediately imaged 
in a micro-PET scanner. We found that most of the protein rapidly accumulated in the 
kidneys (Figure 17a) in agreement with previous biodistribution studies84,96,158. A key 
advantage of 18F over other nuclides is the improved resolution of the PET images 
obtained, up to five fold101. To illustrate this, we compared images obtained using 68Ga-
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DOTA-leptin against those obtained with 18F-FBA-leptin. As expected, the resolution of 
the micro-PET images obtained with 18F-FBA-leptin was substantially improved over 
images produced with 68Ga-DOTA-leptin. Thus, while imaging 68Ga-DOTA-leptin 
demonstrated binding to the kidney in mice (Figure 17b), imaging using 18F-FBA-leptin 5 
clearly reveals binding specifically in the cortex of the kidney, with less binding in other 
regions (Figure 17a).  This pattern is consistent with the uptake of the hormone in the 




Figure 17. a) Serial coronal PET images of ob/ob mouse kidneys, injected with 68Ga-




2.5 Toward 18F-labeling of lysine residues using aminooxyacetic acid-modified side 
chains 
 One alternative approach to 18F-labeling of leptin would be to adopt a lysine side-
chain modification technique, similar to the DOTA modification method (Section 2.2). 
Lysine directed side-chain modification using 18F has been previously described using 
18F-fluorobenzoic acid, succinimide ester (FSB), and applied to a variety of 
substrates122,159. Similarly, Chang et al. labeled the side chains of albumin with 
hydrazinonicotinic acid, succinimide ester, and subsequently conjugated 18F-FBA to 
generate a hydrazone product125. We were attracted to the latter technique, owing to our 
experience with 18F-FBA, and the finding that aniline catalyzes reactions of this 
type156,157,160. However, we were concerned that the stability of a hydrazone containing 
conjugate would be insufficient for the study of leptin biodistribution of leptin in vivo, 
based on previous reports revealing degradation of 18F-FBA labeled hydrazone 
conjugates in mildly acidic solution118. Although, to our knowledge no direct comparison 
has been made between the stability of oxime and hydrazone conjugates in vivo, a recent 
model study revealed greater stability of oximes as compared to hydrazones in aqueous 
buffers161. Thus, we envisioned a leptin labeling approach in which aminooxy groups 
could be installed on lysine side chains, which could be subsequently derivitized with 18F-
FBA, to generate the stable oxime linkage. 
 A method to generate aminooxy-derivitized proteins by native chemical ligation 
was developed by Shao et al., who found that 1M methoxylamine could be used to 
deprotect an isopropylidene protecting group on an aminooxyacetic acid moiety in the 
context of a small protein, CCL-5 (RANTES)162. Thus, we devised a synthetic strategy in 
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which the lysine side chains and N-terminus of leptin could be modified using 
isopropylidene-aminooxyacetic acid, succinimide ester (6), deprotected using 
methoxylamine, and finally labeled with 18F-FBA (Figure 18). We synthesized 6 using 
the method depicted on Figure 19a in two steps in 52% overall yield. We then conjugated 
the reagent to leptin. Similar to leptin labeling with DOTA-NHS, we found that the 
stoichiometry of 6 to leptin determined the degree of leptin labeling (Figure 19b). 
Importantly, treatment with 500 mM methoxylamine on ice overnight removed all of the 
isopropylidene protecting groups following conjugation with 6 in a one pot reaction, in 
70% yield (Figure 19c, d). In preliminary experiments, we found that this aminooxy-
leptin derivative could be labeled with 18F-FBA, in similar yield to aminooxy-leptin 4 
(data not shown). Thus, this technique allows for lysine side-chain modification of 
proteins with aminooxyacetic acid, and is a promising technique for generating 18F-
labeled protein tracers. 
 





Figure 19. Preparation of aminooxy-leptin by modification of lysine side chains. A) 
Synthetic scheme to generate isopropylidene-aminooxyacetic acid-ONHS (6). B) RP-
HPLC of leptin labeled with 6, on the same 0-100% B gradient on a C4 analytical 
column. Four equivalents were used for the red trace, and 20 for the blue trace. The 
number of equivalents of 6 per leptin molecule is indicated above each HPLC peak. C) 
HPLC of deprotected aminooxyacetic acid-leptin following the conjugation with four 
equivalents of 6 (i.e. the red trace from B). D) ESI-MS of the product of the deprotection 
reaction (i.e. the starred peak from panel C) The number of amionooxyacetic acid labels 
per leptin molecule is indicated. 
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2.6 Summary of tracer development 
 
 In conclusion, we have developed two complementary radiolabeled tracers, which 
we term 68Ga-DOTA-leptin, and 18F-FBA-leptin. DOTA labeling of leptin was 
accomplished in an amine directed manner using DOTA-NHS, incorporating an average 
of 4 chelators per protein molecule (fig 7b). DOTA-leptin could readily be labeled with 
68Ga in good yield. A site-specific 18F-labeling strategy was developed, in which an 
aminooxy functional group was first installed on the C-terminus of leptin using EPL, 
which was subsequently derivitized in an aniline accelerated oximation reaction with 18F-
FBA (Scheme 2)163. Thus, the 18F labeling method we have developed is intrinsically site-
specific, and should be readily applicable to other substrates. Furthermore, both tracers 
preserve the ability to bind to and activate ObRb and induce STAT3 signaling, and to 
induce weight loss in ob mice.  A comparison of the imaging properties of the two tracers 
revealed that 18F-FBA-leptin has higher resolution compared to 68Ga-DOTA-leptin, 
allowing for the uptake of the tracer in the cortex of the kidney to be visualized (Figure 
17). Additionally, a lysine directed labeling strategy to generate 18F-FBA-modified leptin, 
based on the conjugation of aminooxyacetic acid to lysine side chains, was developed.  
The use of these tracers to interrogate leptin biology in model systems in rodents and 
primates is discussed in chapters 3 & 4, and an extensive comparison of our tracers to 
others in the literature is presented in section 5.1. 
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Chapter 3. Imaging leptin biodistribution by PET reveals clearance of the hormone 
by Megalin in the cortex of the kidney 
 
The work described in this chapter was performed in close collaboration with G. 
Ceccarini (Friedman lab) 
 
Section 3.1. Leptin half life, clearance, and biodistribution. 
Leptin is a 16 kDa protein hormone, produced and secreted into the circulation by 
adipocytes, which regulates body weight homeostasis by reducing food intake and 
increasing energy expenditure19,24. Leptin also signals nutritional status to several other 
physiological systems and modulates their function. Plasma leptin levels are directly 
proportional to the amount of adipose tissue mass13, and its major site of action is in the 
hypothalamus, where it binds and activates the leptin receptor (ObR). In addition, a 
number of non-ObR binding partners interacting with leptin have been identified, but 
their physiological significance is unknown44,45,49,50. Leptin action in the central nervous 
system is both necessary18 and sufficient52 to generate many of the effects of the hormone. 
Additionally, the hormone has direct effects on some peripheral tissues, modulating their 
function (see section 1.3)62,64,67,75. In particular, leptin has a short half-life which follows 
biphasic kinetics84-87.  All available evidence suggests that leptin is cleared by the kidney, 
as would be expected based on its small size84,87,89-91,158,164,165. However, the molecular 
mechanism underlying this uptake remains unclear. The kidney expresses both ObR and 
the multiligand endocytic receptor megalin50,166,167. Recently, leptin was found to bind to 
an L2 yolk sac tumor cell line expressing megalin. Furthermore, purified megalin binds 
 57 
to leptin with an apparent Kd of 200 nM as revealed by quartz crystal microbalance 
(QCM) analysis50, a technique analogous to surface plasmon resonance which allows the 
monitoring of protein-protein interactions on surfaces168. Thus, both megalin and ObR are 
candidate receptors for leptin uptake in the kidney. 
In vivo imaging of leptin biodistribution could be used to characterize the 
molecular mechanism of leptin uptake in various organs in animal models. Positron 
emission tomography (PET) is well suited for this purpose due to mm scale resolution, 
high sensitivity, and ease of quantification112.  Furthermore, by using the appropriate 
genetically modified animals, the role of various receptors in regulating biodistribution 
can be determined. Herein we describe the application of two tracers, 18F-FBA-leptin163 
and 68Ga-DOTA-leptin (see chapter 2), to micro-PET imaging in various rodent and 
primate models. We found that leptin was rapidly taken up in a saturable manner in the 
kidney, and that this uptake was dependant on the multiligand endocytic receptor 
megalin.  
 
Section 3.2 Whole body PET scans in rodents and rhesus macaques using 18F-FBA-
leptin and 68Ga-DOTA-leptin 
Firstly, we analyzed the biodistribution of leptin in normal mice and rats.  In 
Figure 20a we show a typical whole body image of a leptin deficient (ob/ob) mouse 
injected with 68Ga-DOTA-leptin, imaged by micro-PET for an hour. The tracer 
accumulates principally in the kidneys, but also in other visceral organs such as liver and 
spleen, and in the head. The tracer was largely absent from fat and brain. The low level of 
uptake in the bladder (2.2% of total injected dose) likely represents 68Ga-DTPA, an 
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impurity of the radiochemical synthesis, which is known to be rapidly cleared to the 
urine169. Similar results were obtained with the 18F-FBA-leptin tracer as shown in Figure 
20b. The improved anatomical definition of 18F compared to 68Ga allowed us to observe 
the specific accumulation of the tracer in the periphery of the kidney (cortex) rather than 
the inner portion of the organ (medulla, Figures 18, 19b, e). This finding was confirmed 
using the 68Ga-DOTA-leptin tracer in a rat model, where the larger size of the animal 
permits visualization of the cortex, despite the lower resolution of the 68Ga isotope  
(Figure 20c). Uptake in the proximal femur was also observed in the rat images, 
suggesting uptake in bone marrow. To test if a similar biodistribution pattern could be 
also observed in primates, we imaged rhesus macaques using 68Ga-DOTA-leptin as a 
tracer. The high definition of the PET-CT scan confirmed the renal cortical uptake of the 
tracer (Fig 19d). The fact that both 68Ga-DOTA-leptin and 18F-FBA-leptin provide similar 
images, that these patterns of distribution are consistent with previous biodistribution 
studies92,96, and are consistent between species, strongly suggests that the pattern of 
radioactivity observed in these images coincides with the authentic biodistribution of 
leptin. 
Urine formation occurs in the renal tubules, which travel from the cortex of the 
kidney (proximal convoluted tubules) deep into the medulla (loop of Henle), and return to 
the cortex (distal convoluted tubules, Figure 20e, f). A previous study, in which 125I leptin 
was injected into mice, and the biodistribution subsequently analyzed ex-vivo by 
autoradiography, suggested that leptin is taken up in the proximal convoluted tubule50. 
Taken together with these previous results, our data suggest that leptin is taken up by the 
proximal convoluted tubule within the cortex of the kidney. 
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Figure 20. Whole body PET images of mice, rats, and rhesus macaques reveal that leptin 
is taken up in the cortex of the kidney in mammals. The images are overexposed to reveal 
areas with a lower level of uptake. a) Whole body PET maximum intensity projection 
(MIP) image of a leptin deficient (ob/ob) mouse injected with 68Ga-DOTA-leptin. Renal 
uptake of leptin in ob/ob mice is 65.1% ± 3.5% while the bladder is only 2.2 ± 0.2% over 
30 min. Uptake in other organs is lower than this per volume. b) Whole body PET 
coronal MIP image of an ob/ob mouse injected with 18F-FBA-leptin, with inset of kidneys 
with lowered contrast, revealing uptake of the hormone in the cortex of the kidney. c) 
Whole body PET coronal MIP of a Sprague-Dawley rat injected with 18F-FBA-leptin, 
with inset with lowered contrast, revealing uptake of the hormone in the cortex of the 
kidney. d) Coronal section of a PET-CT fusion image of a rhesus monkey injected with 
68Ga-DOTA-leptin, revealing uptake of the hormone in the cortex of the kidney e, f) 
Simplified diagram of kidney and renal tubular anatomy. 
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Section 3.3. Quantitative analysis of renal uptake of leptin  
One of the strengths of PET imaging is quantitative kinetic analysis of uptake in 
organs. We therefore generated time vs. activity curves in the kidney and bladder by 
drawing regions of interest on the aforementioned anatomical regions of the micro-PET 
images. First, we compared the performance of our two tracers. We found that 18F-FBA-
leptin accumulated rapidly in the kidneys, but then the kidney radioactivity began to 
decrease and move to the bladder as time progressed (Figure 21a). In contrast, 68Ga-
DOTA-leptin uptake increased continually in the kidney over the course of the scan, 
while the level in the bladder remained consistently low (Figure 21a). Radiochemical 
HPLC analysis of the urine of the 18F-FBA-leptin injected animals revealed that the tracer 
had been metabolized to uncharacterized byproducts (Figure 21b). Since 18F-FBA-leptin 
is stable in serum in vitro, and in vivo (Figure 16a, c), this metabolite is probably formed 
following endocytosis of leptin by proximal convoluted tubule cells, where it diffuses out 
into the urine. It is interesting to note that a similar phenomenon was observed in the 
hepatobiliary clearance of 18F-FBA labeled LDL particles128. Previous analysis of 111In-
DOTA labeled antibody fragments has demonstrated that the final product of intracellular 
metabolism is 111In-DOTA-lysine, which is retained in lysosomes170. Thus, it is likely that 
68Ga-DOTA-leptin is similarly degraded to 68Ga-DOTA-lysine. Tracers which are 
retained intracellularly following degradation are termed “residualizing tracers171.” Thus, 
we used 68Ga-DOTA-leptin for all further quantitative analysis, as the fact that it is 





Figure 21. 68Ga-DOTA-leptin is a residualizing tracer, while 18F-FBA-leptin is not. A) 
Representative time activity curves of organ uptake of 68Ga-DOTA-leptin and 18F-FBA 
leptin in mouse kidneys and urinary tract. Organ uptake is defined as the total activity 
quantified in an organ, divided by total body radioactivity, with both quantified by region 
of interest (ROI) analysis of PET scans. B) Radiochemical HPLC analysis of urine from a 
mouse injected with 18F-FBA-leptin indicating degradation of the tracer after one hour. 
For reference HPLCs of intact 18F-FBA-leptin on the same gradient see figures 15b, 16. 
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Three wild type C57BL/6J mice were scanned after injection of 68Ga-DOTA-
leptin, and quantification of kidney and bladder uptake on the resulting micro-PET 
images revealed that 68.2 ± 1.5% and 3.1%  ± 0.6% of the tracer was taken up over 30 
minutes, respectively (Figure 22a, e). Radiochemical HPLC analysis of kidney extracts 
isolated from mice, which had been injected with the tracer, revealed only a peak at 3 
min, indicating that the leptin had been degraded at later time points (presumably to 68Ga-
DOTA-lysine, see above). When co-injected with a 30 fold excess of cold ligand, 23.7 ± 
2.2% of the leptin was displaced from the kidney to the bladder, with 47.3 ± 2.0% 
retained in the kidney (Figure 22c, e). Radiochemical HPLC analysis of the urine of these 
animals revealed a peak at 21.6 min, the characteristic retention time of leptin on this 
gradient, indicating that intact leptin is displaced from the kidney receptors (Figure 22d). 
Thus, micro-PET imaging of 68Ga-DOTA-leptin biodistribution in mice reveals the 
presence of a saturable uptake system in the cortex of the kidney. 
We then confirmed these results using ex-vivo biodistribution analysis. In these 
experiments, a radiotracer is injected (in this case 68Ga-DOTA-leptin or commercially 
available 125I-leptin), and following a period of time, the animals are sacrificed, and the 
radioactivity in the corresponding tissues counted. Thus, these experiments are analogous 
to PET imaging experiments, with only one time point - when the animal is sacrificed. 
The advantage of this technique is that a smaller radioactive dose need be injected to 
quantify tissue uptake (under 10 ng vs. 20 µg in a PET experiment), potentially 
minimizing effects of receptor saturation. In contrast to PET imaging experiments, the 
addition of competing cold leptin increases the amount of protein accumulating in the 
kidney in this analysis (Figure 23a). This is probably due to the fact that peripheral 
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receptors only become saturated when cold leptin is co-injected. When peripheral 
receptors are saturated, a much higher level of protein is delivered to the kidney, probably 
explaining the paradoxical increase seen in Figure 23a. A similar phenomenon was 
observed in PET imaging experiments in rhesus macaques (see section 4.4, Table 4, 
Figure 34). In order to exclude the contribution of increased protein delivery to the 
kidney resulting from saturation of peripheral ObR, we present the biodistribution on 
Figures 22b and c as a ratio of (urinary leptin / kidney leptin + urinary leptin). This 
analysis excludes the contribution of increased delivery of leptin to the kidney via the 
bloodstream, and instead quantifies only binding within the tubules of the kidney. When 
analyzed in this manner, biodistribution experiments performed ex-vivo using 68Ga-
DOTA-leptin and 125I-leptin similarly confirmed that kidney binding can be partially 
displaced to the urine (Figure 23b, c). These results mimic the pattern observed via PET 
imaging. Therefore, uptake of leptin in the tubules of the kidney is partially saturable in 





Figure 22. Leptin uptake in the kidney is partially saturable in mice as detected by PET imaging. 
a) Coronal maximum intensity projection (MIP) of a C57Bl6 wild type mouse injected with 
68Ga-DOTA-leptin, with inset of radiochemical HPLC analysis (b) of homogenized kidneys one 
hour post injection with 68Ga-DOTA-leptin c) Coronal MIP of a C57Bl6 wild type mouse co-
injected with 68Ga-DOTA-leptin and 650 µg leptin, with inset of a radiochemical HPLC analysis 
of the urine 30 minutes post injection (d). e) Time activity curves of the kidney of C57Bl6 wild 
type mice injected with 68Ga-DOTA-leptin in the presence or absence of 650 µg leptin. Kidney 
uptake on the Y-axis is defined as the total radioactivity quantified in the kidney, divided by total 
body radioactivity, with both quantified by region of interest (ROI) analysis. All data are 
reported as means (n=3) ± s.e.m. Statistical significance of the difference between the two 
groups was assessed by Student’s T-test,  p< 0.01. 
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Figure 23. Ex-vivo biodistribution analysis reveals saturable uptake in the kidneys of ob 
and wild type mice. A) Ex vivo biodistribution analysis of 125I leptin in wild type and 
ob/ob mice reveals an increase in accumulation of leptin in the kidney when coinjected 
with cold leptin. B, C) Ex vivo biodistribution results of 125I-leptin (B) or 68Ga-DOTA-
leptin (C) in ob/ob and wild type C57Bl6 mice. The fraction of radioactivity appearing in 
the urine divided by the activity in the kidney plus urine is represented on the Y-axis. n= 
2-3 ± S.E.M. 
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Section 3.4. Comparison of kidney uptake of leptin in ob/ob and ObRΔ/ob/ob mice  
In order to test if the ObR is required for the uptake of leptin in the kidney, we 
compared wild type mice, leptin deficient (ob/ob) and leptin/leptin receptor deficient 
mice (ObRΔ/ob/ob).  ObRΔ/ob/ob mice have a functional knock out for all the isoforms 
of ObRs and are also leptin deficient. This model allows us to dissect the role of ObRs 
without the potential confounding factor of elevated leptin levels associated with the 
receptor deletion. Results from ObRΔ/ob/ob can therefore be directly compared to those 
obtained in ob/ob littermates. Time activity curves, obtained by ROI analysis of PET 
images of renal uptake in the three experimental groups are superimposable, suggesting 
either that ObR mediated uptake is saturated in this model, or that ObR mediated uptake 
is very low in this organ (Figure 24a).    
In order to exclude the possibility that saturation of ObR is responsible for the 
identical levels of uptake in the kidney in PET imaging, biodistribution experiments were 
performed in the same animal strains using 125I-leptin. In this assay, substantially less 
leptin accumulates in the kidneys, owing to the fact that there is no saturation of ObR 
dependant binding sites, as is the case in micro-PET imaging experiments (e.g. compare 
Figure 24a, b). There is no statistically significant difference in the uptake of 125I-leptin in 
the kidney in wild type, ob/ob, and ObRΔ/ob/ob mice as assayed by ex vivo 
biodistribution analysis (Figure 24b). However, when corrected for the slightly higher 
blood levels of 125I-leptin in ObRΔ/ob/ob mice (see chapter 4 for a full discussion of this 
analysis), there is a trend of reduced uptake in the kidneys of ObRΔ/ob/ob vs ob/ob mice 
(Figure 24c, not statistically significant by Student’s one-tailed t test, p value of 0.054). 
This suggests that there may be a low level of ObR mediated uptake in the kidneys of 
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mice, which is less than that mediated by other mechanisms. However, ObR mRNA 
could not be detected in the kidney in rhesus macaques by northern blotting172, suggesting 
that ObR could not be involved in the uptake of leptin of the kidney in rhesus macaques. 
Taken together, our data indicate that ObR mediated uptake is insufficient to account for 
the very high level of uptake of leptin in the kidney, and another mechanism must 





Figure 24. ObR does not mediate the majority of leptin uptake in the kidney. A) A 
comparison of the uptake of 68Ga-DOTA-leptin in the kidneys of wild type C57Bl6, 
ob/ob, and ObRΔ/ob/ob mice as judged by micro-PET imaging. Kidney uptake on the Y-
axis is defined as the total radioactivity in the kidney, divided by total body radioactivity, 
with both quantified by region of interest (ROI) analysis. B) A comparison of the uptake 
of 125I-leptin in the kidneys of wild type C57Bl6, ob/ob, and ObRΔ/ob/ob mice as judged 
by biodistribution analysis. Kidney uptake on the Y-axis is defined as the total 
radioactivity quantified in the kidney, divided by total body radioactivity (n = 3-4 ± 
s.e.m.) C) A comparison of the uptake of 125I-leptin in the kidneys of wild type C57Bl6, 
ob/ob, and ObRΔ/ob/ob mice as judged by biodistribution analysis, following correction 
for blood radioactivity. Kidney uptake on the Y-axis is a dimensionless variable, defined 
as the total radioactivity quantified in the kidney divided by the mass of the kidney, 
divided by the fraction of injected dose per gram of blood (i.e., the standard uptake value 
of leptin in the kidney when compared against the reference of radioactivity in the blood, 
n = 3-4 ± s.e.m). 
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Section 3.5 Quantitative analysis of renal uptake and metabolism of leptin in 
megalin knockout mice 
We then tested the role of megalin (gp330/LRP2) in the kidney uptake of leptin. 
Megalin is a 600 kDa type I glycoprotein receptor, which is expressed is various tissues 
in mammals including the proximal convoluted tubule of the kidney, the choroid plexus, 
and other sites167. Megalin has a similar domain organization to the LDL receptor, with an 
extracellular domain consisting of four clusters of cysteine rich LDL receptor type A 
repeats, which are believed to mediate ligand binding, separated by seventeen EGF-type 
repeats each. Megalin is known to bind to a variety of ligands, including albumin, 
apolipoproteins, various vitamin and hormone carrying proteins such as thyroglobulin 
and vitamin-D binding protein, and low molecular weight hormones such as insulin, 
prolactin, and parathyroid hormone, and mediate their clearance in the proximal 
convoluted tubule of the kidney166,167. Leptin had been previously shown to be 
endocytosed and degraded by the yolk sac L2 tumor cell line (which expresses 
megalin173) and to bind to megalin in vitro using QCM analysis50. Additionally, 
antibodies against megalin were able to co-immunoprecipitate exogenously added leptin 
from a choroid plexus cell line, and siRNA directed against megalin reduced uptake of 
leptin into the brain in mice174. Taken together, these results suggest that leptin binds to 
megalin in L2 and choroid plexus cells. Furthermore, these studies suggest the hypothesis 
that leptin clearance may be mediated by megalin in the proximal convoluted tubule of 
the kidney, and that leptin transport into the CSF may be mediated by megalin. 
In order to test if megalin was responsible for the kidney uptake of leptin in vivo, 
we obtained mice with a kidney specific gene deletion of the receptor megalin (termed 
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megalinlox/lox, ApoEcre, kind gift of T. Willnow, Max-Delbrueck-Center for Molecular 
Medicine, Berlin)175. In this model, cre recombinase expression in the kidney is driven by 
a fragment of the human apolipoprotein promoter E (apoE) and megalin expression is 
reduced to 10% of normal levels175. We measured leptin levels in urine of megalinlox/lox, 
ApoEcre mice by an Enzyme-Linked ImmunoSorbent Assay (ELISA). Leptin levels are 
undetectable in the urine of rodents158 but in megalinlox/lox, ApoEcre mice levels are 16.7 ± 
2.9 ng/mL (SEM, n=4) indicating a significant leptin loss in urine (Figure 25a). In the 
urine of the megalinlox/lox, ApoEcre mice, leptin is intact as confirmed by western blotting 
(Figure 25b). These results strongly suggest that megalin is required for the reuptake of 
leptin in the proximal convoluted tubule of the kidney. 
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Figure 25. Leptin is released intact in the urine of Megalinlox/loxApoECre mice. A) 
Enzyme-Linked ImmunoSorbent Assay (ELISA) of leptin in the urine of the indicated 
mouse strains. The dotted line represents the limit of detection (n=3 ± s.e.m., statistical 
significance of difference between Megalinlox/loxApoECre and Megalinlox/lox: p<0.001). B) 




We confirmed this hypothesis using PET imaging in the same mouse model. 
Megalinlox/lox, ApoEcre mice were imaged using 68Ga-DOTA-leptin together with their 
littermate megalinlox/loxcontrols. Our results show that in the basal condition, megalinlox/lox, 
ApoEcre mice have a pattern of distribution of 68Ga-DOTA-leptin in the urinary tract that 
is similar to one observed when wild type mice are co-injected with cold leptin (Figure 
26a,b, compare to 21a, c). Accumulation of 68Ga-DOTA-leptin in the bladder is greatly 
increased  (18.7 vs. 3.5% p< 0.01) and in the kidney significantly reduced (54.5 vs. 
63.7%, p<0.05) when compared to controls (Figure 26d, e). Radiochemical HPLC 
analysis of the urine from a megalinlox/lox, ApoEcre mouse revealed the characteristic 21.6 
min peak corresponding to intact leptin (Figure 26c). An 18F-FBA-leptin scan of the same 
mouse model revealed that the residual uptake in the kidney is still concentrated in the 
cortex (Figure 27a), suggesting that the remaining uptake in the kidney is either due to 
the residual megalin expression, or to binding to a second receptor in the cortex of the 
kidney, rather than binding to other locations in the kidney.  
 73 
 
Figure 26. Megalin is required for the uptake of leptin in the kidney in vivo. Coronal MIP 
of a megalinlox/lox control mouse (a) injected with 68Ga-DOTA-leptin and of a megalinlox/lox 
ApoEcre mouse (b) injected with 68Ga-DOTA-leptin. c) Radiochemical HPLC analysis of 
urine recovered from a megalinlox/lox ApoEcre mouse, which was injected with 68Ga-
DOTA-leptin. d, e) Time activity curves of the uptake in the kidney (d) and bladder (e) of 
68Ga-DOTA-leptin in megalinlox/lox ApoEcre (red triangles) and megalinlox/lox (blue squares) 
mice. Kidney or urinary uptake on the Y-axis is defined as the total radioactivity 
quantified in the kidney or bladder plus spilt urine, divided by total body radioactivity, 
with both quantified by region of interest (ROI) analysis. All data are reported as mean ± 
s.e.m. (n=3). Statistical significance of megalin kidney KO versus lox controls: * p < 
0.05, ** p < 0.01.  
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The addition of a 30-fold excess of competing leptin during micro-PET imaging 
led to a further displacement of leptin from the kidney to the urine (Figure 27b, c). A 
comparison of Megalinlox/lox, ApoEcre mice vs. littermate lox controls, imaged using 68Ga-
DOTA-leptin, with co-injection of a 30 fold excess of cold leptin, reveals that the pattern 
of uptake in the kidney and bladder are similar over the first 10 minutes of the scan 
(Figure 27b). However, in the last 20 minutes of the scan, the lox control animals began 
to again to take up leptin in the cortex of the kidney, while Megalinlox/lox, ApoEcre mice do 
not. These results show that the reuptake process in the cortex of the kidney in 
Megalinlox/lox, ApoEcre is exhausted following challenge with competing leptin and unable 
to recover over the course of the scan. These results are consistent with the dramatically 
reduced expression of megalin in the kidneys of Megalinlox/lox, ApoEcre mice. Collectively, 
these data support a model of leptin renal metabolism in which leptin is freely filtered by 
the glomerulus in the kidney and subsequently reabsorbed in the proximal convoluted 





Figure 27. A) 18F-FBA-leptin scan of megalinlox/lox, ApoEcre mice reveals that leptin 
uptake remains restricted to the cortex of the kidneys. B, C) Time activity curves of the 
uptake in the kidney (B) and urine (C) of 68Ga-DOTA-leptin in megalinlox/lox ApoEcre (red 
triangles) and megalinlox/lox (blue squares) mice, when the tracer is injected with a 30 fold 
excess of competing leptin. Kidney or urinary uptake on the Y-axis is defined as the total 
radioactivity quantified in the kidney or bladder plus spilt urine, divided by total body 
radioactivity, with both quantified by region of interest (ROI) analysis. All data are 
reported as mean ± s.e.m. (n=3). 
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Section 3.6. Megalin mediates the uptake and clearance of leptin in the proximal 
tubules of kidney 
 We have described the application of two complementary tracers, 18F-FBA-leptin 
and 68Ga-DOTA-leptin to micro-PET imaging in mice. Imaging in wild type mice and 
rats revealed rapid uptake in the cortex of the kidney. Additionally, lower levels of uptake 
were observed in the visceral organs, head, and bone marrow. Unfortunately, probably 
due to the relatively large molar quantity of tracer that had to be injected in mice, 
peripheral ObR receptors were saturated under the conditions of the experiment (see 
section 5.2 for discussion). Fortunately, this limitation did not apply to PET imaging in 
rhesus macaques (chapter 4). Thus, in order to study quantitative ObR binding in mice, 
we relied on biodistribution analysis (Figure 23, 23b, section 4.3). The unique properties 
of each tracer was required for a full elucidation of the uptake of the hormone in the 
kidney: while 18F-FBA-leptin revealed uptake of the hormone in the cortex of the kidney 
(Figure 20, 19b), 68Ga-DOTA-leptin allowed for quantitative analysis of uptake since it is 
a residualizing tracer. Furthermore, the fact that the biodistribution patterns of both 
tracers are similar gives confidence in the imaging results. 
 Using PET imaging in mice we were able to elucidate the role of the multiligand 
receptor megalin in the clearance of leptin by the kidney. Previous studies had revealed 
that leptin is cleared by the kidney in mice, nonhuman primates, and humans84,85,87-
91,96,158,163. We also found high levels of uptake of leptin in the kidneys in mice, rats, and 
rhesus macaques (Figure 20). Quantification of uptake in the cortex of the kidney by PET 
revealed that 68.2 ± 1.5% of the tracer was cleared by the kidney over 30 minutes. 
Furthermore, by coinjection of a 30 fold excess of leptin, a substantial portion of the 
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hormone could be displaced from the kidney, as only 47.3 ± 2.0% was then taken up. 
Thus, there is a saturable reuptake system for leptin reuptake in the kidney. Recently, 
Hama et al. found that leptin binds to megalin, a protein abundantly expressed on the 
proximal tubules in the kidney50. Additionally, leptin had been previously shown to bind 
to the renal medulla in tissue sections, where ObR is known to be expressed81,83. In order 
to define which receptor was responsible for the clearance of the hormone in vivo, we 
obtained mice with a kidney-specific deficit of the multiligand clearance receptor 
megalin (Megalinlox/lox, ApoEcre), and mice deficient in ObR (ObRd/ob/ob). The finding 
that the megalin deficient mice lost leptin in the urine suggested that this receptor was 
required for the clearance of leptin. This finding was confirmed by PET imaging, where a 
significant reduction of leptin uptake in the kidney was observed in mice with a kidney 
specific deficit of megalin. By contrast, mice lacking ObR had no apparent change in 
kidney uptake of the hormone, as detected by PET imaging. At present, we cannot 
exclude the presence of a low level of ObR dependant uptake in the kidney, as 
biodistribution analysis revealed a small, non-statistically significant difference in the 
uptake of leptin in the kidney when comparing Ob/ob and ObRd/ob/ob mice (Figure 24c). 
Thus, taken together with the previous data regarding clearance of the hormone, our PET 
study reveals that leptin is freely filtered in the glomerulus of the kidney, where it is 
taken up in the cortex, in a manner that requires the transporter megalin. The implications 
of this finding are further discussed in section 5.3.  
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Chapter 4. Ex vivo biodistribution in mice and PET imaging in rhesus macaques 
reveals ObR dependant uptake of leptin in the brain and a role for leptin in 
hematopoiesis 
 
Experiments performed in this chapter were the product of a close collaboration 
with G. Ceccarini (Friedman lab) and E. Butelman (Kreek lab) 
 
Section 4.1. Why study ObR biodistribution and receptor occupancy? 
 The leptin receptor ObR is widely expressed in peripheral tissues and in the CNS, 
and its function in the hypothalamus is essential for normal body weight and energy 
homeostasis (see section 1.3)19,24. In addition, leptin modulates the function of several 
peripheral tissues, in part by direct action of ObR in those organs. To date, despite 
extensive study of ObR mRNA expression15,37,176, and leptin binding in tissue sections83, 
there is no comprehensive description of leptin biodistribution in vivo. The advantage of 
biodistribution analysis is that it takes into account the physiological (or pathological) 
pattern of functional cell surface receptor expression. Furthermore, by studying the 
appropriately genetically modified animals, uptake in organs and tissues can be ascribed 
to specific receptors. Additionally, current models of leptin resistance, which is present in 
most obese humans, predict altered biodistribution of the hormone27,177,178. Finally, 
biodistribution analysis could be used to discover novel roles of leptin in an unbiased 
approach. 
 Micro-PET imaging in mice using 68Ga-DOTA-leptin and 18F-FBA-leptin was 
used to elucidate the mechanism of leptin clearance by the multiligand receptor megalin 
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(see chapter 3). However, we were unable to study ObR mediated uptake using micro-
PET in mice, owing to the fact that the specific activity of our tracers is moderate, and a 
relatively large dose of the hormone (15-30 µg) must be injected to enable visualization 
of the hormone. Unfortunately, this is a common problem in micro-PET imaging, and is 
particularly prevalent in mice, which are the most convenient animals for genetic 
modification179,180. One way to overcome this to this would be to improve the specific 
activity of our tracers, 18F-FBA-leptin, and 68Ga-DOTA-leptin. Potential methods to 
accomplish this are discussed in section 5.1. Another method would be to forgo PET 
imaging altogether, and rely on ex-vivo biodistribution analysis, in which a smaller 
quantity of a radiotracer is injected, the animal sacrificed, and the radioactivity in tissues 
counted. This technique suffers from the limitations that kinetic data is more difficult to 
obtain, and that the animal is destroyed in the experiment - this is particularly 
troublesome for animal models that are difficult or slow to breed (for example 
ObRΔ/ob/ob mice and Megalinlox/lox, ApoEcre). The final way to overcome issues of 
receptor saturation is to use larger animal models such as primates. This is because a 
much smaller dose relative to the mass of the animal need be injected (approximately 100 
fold less in mg/kg). In this section, we describe the application of ex-vivo leptin 
biodistribution analysis to mice, and of PET-CT imaging of leptin biodistribution in 
rhesus macaques. Using these techniques, we found that a subset of tissues were able to 
take up leptin in an ObR-dependant manner. Most prominently, hematopoietic tissues 
have a very high level of uptake of the hormone, suggesting that leptin may play an 
important role in modulating the function of hematopoietic and immune systems by direct 
action of ObR on these cells.  
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4.2 Biodistribution analysis of leptin reveals sites of leptin receptor dependant 
uptake in mice 
 Biodistribution analysis has been previously applied to leptin (see section 1.6), 
principally for the purpose of studying the transport of leptin into the brain17,39,92,181,182. We 
chose to use 125I-leptin for biodistribution analysis for several reasons. Firstly, the labeled 
hormone is commercially available at high specific activity (81 GBq/µmol). Secondly, 
the long half-life of the isotope (60 days) means that one batch can be used for a series of 
experiments. Finally, we chose to use 125I in order to avoid the regulatory problems 
associated in moving animals or radioisotopes in between Rockefeller University (where 
the animals were housed) to Weill-Cornell Medical College (where 18F and 68Ga is 
generated).  
Our goal was to define which tissues have ObR dependant uptake in mice. In 
order to assess this, we investigated four groups of mice on the C57Bl6 background - 
wild type, ob/ob (lacking intact leptin), ObRΔ (lacking all isoforms of the leptin 
receptor), and ObRΔ/ob/ob (mice lacking both leptin and leptin receptor). The generation 
and use of ObRΔ/ob/ob mice is necessitated because ObRΔ mice have very high 
circulating levels of leptin, which would saturate any high affinity binding. By comparing 
the biodistribution of leptin in an animal strain with or without competing leptin, 
saturable binding sites can be identified. Secondly, by comparing the biodistribution of 
leptin Ob/ob vs ObRΔ/ob/ob mice, ObR dependant binding sites can be identified. In a 
typical biodistribution experiment, approximately 10-15 KBq of 125I leptin (specific 
activity 81.4 GBq/µmol), corresponding to approximately 150 fmol or 2.4 ng of leptin is 
injected, in the presence or absence of 650 µg competing leptin. It is important to note 
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that this injected dose is approximately a 10000 fold reduction in the amount of leptin 
injected in a typical micro-PET imaging experiment (20-30 µg), which could not saturate 
binding sites. After 15 minutes, the animals are sacrificed by decapitation, the organs 
harvested, weighed, and the radioactivity contained therein counted in a gamma counter. 
Table 3A reveals the results of the biodistribution analysis of 125I-leptin in various 
mouse strains.  A comparison of wild type or Ob mice in the absence or presence of cold 
leptin reveals the presence of saturable uptake in the spleen, lung, liver, brain and bone in 
these animals (Figure 28a, c). In ObRΔ mice, no saturable uptake was seen in any organ. 
An increase was seen in the uptake of the hormone in the kidney in Ob and wild type 
mice when co-treated with cold leptin. As discussed in section 3.3, this is probably due to 
the increased delivery of leptin to the kidney, following saturation of peripheral ObR. No 
saturable uptake was seen in the heart in Ob/ob or wild type mice. Broadly speaking, our 
biodistribution results are consistent with prior reports, which found uptake of 125I-leptin 
in the liver, kidney, brain, and bone marrow in mice92, and in the kidney, lungs, spleen, 
and liver in chickens183. 
Next, we tested if ObR was required for the uptake of leptin in these tissues, by 
comparing the uptake in Ob/ob vs. ObRΔ/ob/ob mice. A comparison of Ob/ob vs. 
ObRΔ/ob/ob mice reveals that Ob/ob mice take up a greater amount of 125I-leptin in the 
spleen, lung, liver, brain, bone and fat than their ObRΔ/ob/ob counterparts (Figure 28b, 
c). Thus, there is ObR dependant uptake in these tissues. The fact that there was a 
difference between Ob/ob vs. ObRΔ/ob/ob mice in the uptake of 125I-leptin in the fat, and 
saturable uptake of leptin in the fat of Ob/ob but not wild type mice, suggests that there is 
functional leptin receptor in fat tissue, but that it is saturated under the conditions of the 
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experiment in wild type mice. Alternatively, Ob mice may upregulate ObR in fat tissue to 
compensate for their leptin starved state. 
One major caveat in interpreting the data in this manner is that there is a 
significant variation in blood levels of leptin between the different strains of mice (Table 
3a). The cause of this phenomenon is obscure, but may be due to saturation of circulating 
receptors (ObRe), or other intravascular binding sites. In order to correct for this 
phenomenon, we present the same data again on Table 3b, where the uptake in tissues is 
divided by the uptake in the blood, and then multiplied by 1000 by convention to enable 
comparison with published results17,39. This correction allows for a direct comparison of 
the binding potential for leptin in an organ of an animal to that of other organs within the 
same animal or others. A more rigorous method would be to serially take blood samples 
to define an “exposure time” parameter17,184,185. However, given the difficulty in 
generating the correct mouse strains in significant numbers (particularly ObRΔ/ob/ob 
mice, which must be generated from a cross of double ObRΔ/ob heterozygotes) this is an 
intractable problem from a technical standpoint. Nevertheless, given that we are simply 
seeking to define regions of saturable uptake, and to explain which receptor is 
responsible, this analysis is sufficient.  
Broadly speaking, the results from the corrected biodistribution mimic those of 
the unmodified numbers, revealing saturable, leptin receptor dependant uptake in the 
spleen, lung, liver, brain, bone, and fat. An additional interesting observation is that there 
is higher binding in all tissues in Ob mice vs. wild type mice, suggesting either that Ob 
mice upregulate ObR to compensate for their leptin starved condition, or that wild type 
mice have their binding sites partially saturated under physiological conditions. Our data 
 83 
reveal slightly higher uptake of 125I-leptin in the brain than previous reports, possibly 
owing to either different specific activity of our 125I-leptin preparation, different mouse 
strains (CD-1 vs. C57Bl6 in our study) or different dissection technique (Figure 29, value 
of 55 in wild type mice, compare to approximately 25 in intact animals17, but ranging 
from 10-125 using perfusion techniques 39,182). A comparison of the brain uptake of leptin 
in Ob/ob and ObRΔ/ob/ob mice reveals a significantly different level of uptake in the 
brain, implying that ObR is required for uptake of leptin in the brain. These data 
represent the first unambiguous demonstration that leptin receptor is required for full 
transport and binding of leptin to the brain under intact physiological conditions. Using a 
capillary perfusion technique, in which mouse brains were perfused with 125I-leptin, 
Hileman et al. found a significant difference between the uptake of 125I-leptin when 
comparing wild type and ObRΔ mice39. Our data confirm this finding, and extend it to 
find that the reduced uptake also occurs in mice under physiological, non-brain perfused 
conditions. Furthermore, this finding controls for the multiple endocrine and immune 
abnormalities found in Ob and ObRΔ mice. 
 Our data reveal that the highest level of uptake of leptin in the brain is in Ob 
mice. Wild type mice have lower uptake, suggesting that their uptake system into the 
brain is either lower capacity or partially saturated, consistent with previous 
observations182. All animals with competing cold leptin, or lacking leptin receptor 
altogether, have lower levels of leptin uptake in the brain. Taken together, our data reveal 
that in mice, that there is saturable, ObR dependant uptake of leptin in the spleen, lung, 




Organ WT  WT + cold leptin Ob/ob 
Ob/ob + 
cold leptin ObRΔ 
ObRΔ + 
cold leptin ObRΔ/ob/ob 
Blood 7.24 ± 0.13 4.33 ± 0.09 3.90 ± 0.16 3.16 ± 0.21 4.33 ± 0.16 2.56 ± 0.38 6.05 ± 0.45 
Spleen 20.40 ± 4.02 2.42 ± 0.31 15.70 ± 1.80 2.96 ± 0.73 1.50 ± 0.42 1.33 ± 0.39 5.84 ± 0.39 
Lung 11.47 ± 2.93 3.23 ± 1.45 11.05 ± 0.56 3.37 ± 0.32 2.90 ± 0.84 1.86 ± 0.43 3.89 ± 0.43 
Liver 4.28 ± 0.14 1.44 ± 0.13 4.08 ± 0.53 1.36 ± 0.22 1.09 ± 0.01 0.84 ± 0.22 1.80 ± 0.22 
Heart 3.70 ± 0.36 2.66 ± 0.10 1.85 ± 0.15 2.03 ± 0.04 2.15 ± 0.16 1.98 ± 0.33 1.98 ± 0.33 
Brain 0.40 ± 0.01 0.19 ± 0.02 0.26 ± 0.02 0.14 ± 0.01 0.15 ± 0.03 0.09 ± 0.02 0.18 ± 0.02 
Bone 3.52 ± 0.055 1.23 ± 0.44 1.55 ± 0.06 0.71 ± 0.05 0.90 ± 0.06 0.65 ± 0.07 0.88 ± 0.07 
Fat 1.04 ± 0.18 1.14 ± 0.07 0.50 ± 0.06 0.30 ± 0.05 0.37 ± 0.03 0.23 ± 0.03 0.35 ± 0.04 
Kidney 49.1 ± 12.1 125 ± 13 27.6 ± 2.4 96.5 ± 13.9 60.7 ± 5.5 85.6 ± 3.1 29.9 ± 3.9 
 
B) 
Organ WT  WT + cold leptin Ob/ob 
Ob/ob + 
cold leptin ObRΔ 
ObRΔ + 
cold leptin ObRΔ/ob/ob 
Spleen 2817 ± 557 558 ± 73 4028 ± 493 936 ± 240 348 ± 53 519 ± 171 966 ± 130 
Lung 1584 ± 405 745 ± 335 2835 ± 187 1065 ± 123 672 ± 196 727 ± 200 644 ± 57 
Liver 590 ± 22 333 ± 30 1047 ± 142 428 ± 76 253 ± 10 332 ± 100 298 ± 49 
Heart 510 ± 51 615 ± 26 475 ± 44 644 ± 43 498 ± 42 773 ± 174 445 ± 31 
Brain 55 ± 2 44 ± 6 66 ± 5 43 ± 5 36 ± 7 34 ± 9 30 ± 4 
Bone 486 ± 12 295 ± 12 398 ± 22 225 ± 21 209 ± 17 254 ± 48 146 ± 14 
Fat 145 ± 25 263 ± 18 127 ± 17 95 ± 16 86 ± 7 90 ± 18 58 ± 7 




5041 4945 ± 450 
 
Table 3. Summary of biodistribution analysis of 125I-leptin in various mouse models. A) 
Uptake in % injected dose/g tissue (i.e., the percent of the total injected dose in a tissue, 
divided by the weight of that tissue). Results are an average of 3-4 experiments ± s.e.m. 
B) Uptake in the indicated tissues when corrected for blood values. Uptake values from A 
were divided by the blood uptake value, and multiplied by 1000 to obtain a normalized 
standard uptake value. Results are an average of 3-4 experiments ± s.e.m. 
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Figure 28. Biodistribution results using 125I reveal saturable and leptin receptor 
dependant uptake in tissues. Animals were sacrificed 15 minutes after injection with 15 
KBq 125I-leptin, and the indicated tissues weighed and counted in a gamma counter. The 
% of the total injected dose in the indicated tissue, divided by the weight of the tissue is 
plotted on the Y-axis. A) A comparison of wild type and Ob/ob mice with and without 
coinjection with 650 µg leptin. B) A comparison of Ob/ob vs ObRΔ/ob/ob. C) A 
comparison of the uptake of leptin in the brain in various animal models. 
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Figure 29. Uptake of 125I-leptin in the brain is mediated in part by ObR. Animals were 
sacrificed 15 minutes after injection with 15 KBq 125I-leptin, and the brain and blood 
were collected, weighed, and counted in a gamma counter. On the Y axis the uptake is 
represented as 1000 times (% Injected dose / mass of brain in mg) / (% injected dose in 
blood / mass of blood in mg), i.e. the standard uptake value of leptin in the brain when 
using the blood as a reference tissue (n = 3-4 ± s.e.m). Statistical significance was 
assessed between the Ob/ob group and the other groups connected by lines by Student’s 
one-tailed t-test, 0.05 < p. 
 
Section 4.3. A rationale for imaging of leptin biodistribution in non-human primates 
 The encouraging results generated from micro-PET imaging and biodistribution 
studies in rodents led us to consider other animal model systems with greater relevance to 
leptin biology in man. Rhesus macaques are a commonly used species of laboratory 
monkey in which the basic physiology of leptin has been characterized, using essentially 
the same approaches followed in mice. The cloning of rhesus macaque leptin followed 
shortly after the cloning of mouse and human leptin186. The sequence homology of rhesus 
to mouse and human leptin is 84% and 91%, respectively (Figure 30). Rhesus ObR is 
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found in adipose tissue, liver, choroid plexus, and hypothalamus, where it is expressed 
principally in the arcuate and ventromedial hypothalamic nuclei in POMC and AgRP 
neurons172,187. Leptin levels in macaques are correlated with the total weight of the animal, 
and centrally administered human leptin is able to induce weight loss while peripherally 
administered leptin is not188,189. Leptin has a biphasic half-life in macaques with a second-
phase half life of 96 minutes86. Leptin also appears to play a role in the immune system in 
macaques, as they produce leptin in response to endotoxin injection190.  Furthermore, 
leptin treatment reduces the production of other inflammatory factors such as IL-6, TNF-
α, and cortisol in endotoxin injected monkeys191. Thus, the role of leptin in energy 
homeostasis and regulation of immunity superficially resembles the homologous system 
in mice. It is likely that further study of leptin physiology in macaques will yield useful 
information of relevance to humans. 
PET imaging of leptin biodistribution in rhesus macaques provides additional 
information which could not be obtained in mice. Firstly, leptin function and physiology 
is more likely to mimic that in humans due to the closer evolutionary relationship 
between the species. Secondly, due to their larger size, Macaques can be imaged in a 
clinical PET-CT scanner. Thus, the functional metabolic information provided by the 
PET scan can be fused to the anatomical information provided by the CT scan. 
Additionally, a lower dose of isotope relative to the size of the animal can be injected, 
which reduces saturation of receptor binding sites. Therefore, we decided to undertake a 




Figure 30. Sequence alignment of leptin in mammalian species referred to in this section. 
Sites of divergence are highlighted in red. Residues which are believed to be essential for 
ObR binding or activation133,134 are highlighted in blue. 
 
4.4. PET imaging of leptin biodistribution in rhesus macaques. 
In a typical PET-CT imaging experiment, 68Ga-DOTA-leptin is introduced via a 
venous catheter, with or without 1 mg of competing cold leptin administration prior to 
tracer administration. PET imaging of rhesus macaques injected with 68Ga-DOTA-leptin 
revealed a high level of uptake in the sphenoid bone, mandibles, head of the humeri, 
vertebral bodies, pelvic bones, sternum, and kidney (Figure 31a-d). PET-CT fusion 
images reveal that the tracer is confined to the inner portion of these bones (Figure 32).  
One possibility is that this binding represents an artifact of imaging the biodistribution of 
murine leptin in a rhesus monkey. In order to exclude this possibility, we performed a 
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competition experiment in which rhesus leptin was used to displace 68Ga-DOTA-
(murine)-leptin in a PET imaging experiment. Thus, we expressed rhesus leptin in E. coli 
and purified and refolded it as described in the methods (Figure 33A, B). In the 
aforementioned (murine) ObRb-STAT3-luciferase activation assay (Figure 6), rhesus 
leptin had identical activity to human leptin (Figure 33C, EC50 of 0.44 nM). In a 68Ga-
DOTA-leptin scan with the coinjection of a 20-fold excess of rhesus leptin, a striking 
difference was observed, and the tracer localized almost exclusively to the kidney (Figure 
31e, f).  Nearly identical results were obtained with a similar competition scan with 
murine leptin (data not shown). Thus, the binding of 68Ga-DOTA-leptin to these tissues 
almost certainly mimics the binding activity of rhesus leptin.
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Figure 31. Maximum intensity projections (MIPs) of PET scans using 9 – 25 MBq of 
68Ga-DOTA-leptin (corresponding to approximately 50 µg) as a tracer in rhesus 
macaques. A,B) Subject #1, in coronal and sagittal planes. C,D) Subject #2 in coronal 
and sagittal planes. E,F) Subject #1, with 1 mg of competing cold rhesus leptin co-




Figure 32. PET-CT fusions of two rhesus macaques injected with 68Ga-DOTA-leptin 
(10-30 MBq per experiment). A) Subject #1, sagittal view at midline. B) Subject #1, axial 
view at the base of the skull. C) Subject #2, sagittal view at midline. D) Subject #2, axial 
view at the base of the skull. E) Subject #2, axial view through the L4 vertebral body. F) 




Figure 33. Expression and purification of rhesus leptin. a) SDS-PAGE on a 4-20% 
gradient gel of purified rhesus leptin, stained with Coomassie blue. b) ESI-MS 
reconstruct of purified rhesus leptin (Calculated mass 16529.1, obtained 16529.7 ± 4.1). 
c) Leptin receptor-STAT3 dependant luciferase assay comparing the activity of rhesus 
leptin and human leptin obtained from a commercial source. EC50 for rhesus leptin = 0.44 
nM (95% confidence intervals 0.37 – 0.53 nM). EC50 for human leptin = 0.42 nM (95% 
confidence intervals 0.32 to 0.54 nM, n = 2 per group ± s.d). 
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The high level of uptake of the tracer in the kidney likely represents uptake in the 
proximal convoluted tubule by the endocytic receptor megalin (see chapter 3). The 
pattern of uptake in the sphenoid bone, sternum, head of the humerus, and vertebral 
bodies mimics that obtained with the bone marrow targeting tracer 18F-fluorothymidine 
(FLT)192. Based on the similarity between the images generated with these two tracers, 
we propose that the high levels of uptake in the axial skeleton represent binding to red 
bone marrow. Red bone marrow is the site of hematopoiesis in adult rhesus macaques, 
and is composed of hematopoietic precursors, blood vessels, and stromal cells such as 
adipocytes and reticular cells. 
Time activity curves of uptake of 68Ga-DOTA-leptin are presented on Figure 34.  
Four distinct patterns of uptake were observed. Firstly, radioactivity in the bone marrow 
stays constant over time course of the scan, at a high level. This pattern suggests the 
presence of a very high level of saturable receptors. The tracer accumulates continually in 
the kidney over the course of the scan, mimicking the effect observed in mice (see Figure 
22e). This pattern is consistent with the clearance of the hormone by the receptor megalin 
in the kidney (see chapter 3). Interestingly, displacement increased the activity observed 
in the kidneys. These results are consistent with a high affinity-binding site in the bone 
marrow (presumably leptin receptor), and a lower affinity site in the kidneys (presumably 
megalin). Thus, in the absence of competing leptin, the tracer is free to bind to peripheral 
leptin receptors. However, in the presence of saturating leptin, binding to the high affinity 
sites is blocked, and leptin is instead filtered by the kidney, where it binds to megalin, in 
a lower affinity interaction. In comparison with mice, the rate of clearance of 68Ga-
DOTA-leptin in rhesus macaques is slower, as judged by the uptake of the hormone in 
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the kidney (compare Figure 22e and 35); this is consistent with a previous comparison of 
leptin pharmacokinetics in mice and monkeys86. In the heart, an identical pattern of 
disappearance of the tracer is observed in the displacement and tracer-only scans. This 
pattern suggests that there is no saturable uptake in the organ, and that the observed 
radioactivity simply represents intravascular leptin. Finally, the liver initially has the 
same level of the tracer, but as the scan progresses, the tracer clears more rapidly from 
organs in the competing scan than in the tracer-only scan. This pattern suggests the 
presence of a low level of saturable receptors in the organ, which is initially 
overshadowed by the blood pool leptin. As the leptin in the blood clears to the kidney, the 
saturable uptake becomes detectable. Thus, collectively these data indicate that there is 
the presence of a very high level of saturable uptake leptin in the bone marrow, and lower 
levels of uptake in the liver. 
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Figure 34. Time activity curves of uptake of 68Ga-DOTA-leptin in rhesus macaques in 
selected organs. Uptake on the Y axis is the fraction of the injected dose in the 
corresponding tissue, i.e. the total radioactivity in the indicated tissue, divided by the total 
body radioactivity, as determined from ROI analysis of the PET-CT fusion scan (average 




4.5. A comparison of mouse biodistribution and rhesus monkey PET results suggests 
a role for leptin in hematopoiesis 
  In order to define the molecular mechanism of leptin uptake in various 
tissues, we performed biodistribution analysis using 125I leptin in mouse models. Using 
this method, saturable, ObR dependant uptake of the hormone was found in the brain, fat, 
spleen, lung, liver, and bone (Figure 28a). Of these tissues, the spleen and bone are sites 
of hematopoiesis in adult mice193. Additionally, biodistribution analysis in mice lacking 
leptin receptor reveals that the uptake in these sites is dependant on ObR (Figure 29). 
Uptake in the fat was relatively low, and saturated in wild type mice, suggesting that 
these receptors are generally saturated under normal physiological conditions. The low 
level of saturable uptake in the brain is consistent with previously published results17,39. 
Importantly, our results provide direct proof that leptin receptor mediates binding in the 
mouse brain, and that this system is not fully saturated under normal physiological 
conditions (Figure 29). At present, our results also suggest a low level of ObR mediated 
leptin uptake in the kidney, in addition to the much higher level of megalin mediated 
uptake, although a larger data set is needed to conclusively prove this hypothesis. Much 
higher levels of ObR dependant leptin uptake were also seen in the lungs, liver, bone, and 
especially in the spleen.  
 In rhesus macaques, saturable uptake of the hormone was found in the bone 
marrow and liver (Figure 34). Uptake in the bone marrow was particularly prominent 
(Figure 31, 32). In adult primates, the bone marrow is the site of hematopoiesis193. 
Unfortunately, the same quantitative technique could not be applied to understanding the 
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biodistribution of leptin using PET imaging in mice. This is because a relatively large 
amount of tracer must be injected in mice (15-30 μg per scan), potentially saturating 
peripheral binding sites. Nevertheless, we were able to see a low level of tracer uptake in 
the bone marrow in rats injected with 68Ga-DOTA-leptin (see Figure 20c). Another 
important result is that the highest level of uptake was observed in the hematopoietic 
system in mice (in the spleen and bone marrow), and in rhesus macaques (the bone 
marrow). Taken together, these results strongly suggest that leptin plays a role in 
modulating the immune and hematopoietic systems by direct action on hematopoietic 
precursors.  
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Chapter 5. Discussion 
 
5.1. A comparison of the properties of 18F-FBA-leptin and 68Ga-DOTA-leptin, and 
potential improvements to the tracers  
 The properties of the three radiolabeled tracers referred to in this thesis are 
presented on Table 4.  68Ga-DOTA-leptin and 18F-FBA-leptin emit positrons, allowing for 
PET imaging, while 125I decays by electron capture to produce β- particles which cannot 
be used for PET imaging.  The specific activity of the PET-imaging tracers is 
comparable, with that of 18F-FBA-leptin being slightly higher than 68Ga-DOTA-leptin. 
The major advantage of the 18F-FBA-leptin tracer is the resolution of the images 
generated.  Thus, while imaging of 68Ga-DOTA-leptin reveals uptake of the tracer in the 
kidney, the higher resolution of 18F-FBA-leptin shows that the protein is absorbed 
principally in the renal cortex (Figure 20, 19). The labeling chemistry and protein 
labeling sites are different, but both PET tracers retain native-like bioactivity (Figures 7, 
14). Finally, the fate of the labeled tracers following receptor binding and endocytosis are 
different: 68Ga-DOTA-lysine a residualizing tracer, while the unidentified metabolite of 
18F-FBA-leptin diffuses freely from cells, as does 125I-iodotyrosine from 125I-leptin treated 
cells (Figure 21). It is important to note that there were no detectable physiological 
effects of any labeled tracers in any PET imaging experiments we performed, 
demonstrating that we were performing our imaging experiments at tracer levels. 
Furthermore, the similar biodistribution pattern generated by all tracers used provides 











5.5 - 11 GBq / 
µmol 9 - 17 GBq / µmol 81 GBq / µmol 
Half-life 68 minutes 110 minutes 60 days 
Imaging 














metabolism Residualizing Diffusible Diffusible 
Table 4. A comparison of the properties of the three radioactive tracers used in this 
thesis. Resolution information is taken from the model study of Sanchez-Crespo et al101. 
 
 
 A comparison of 68Ga-DOTA-leptin to the other 68Ga-chelate labeled proteins 
from the literature is presented on Table 5. The radiochemical properties of our tracer 
compares favorably with the previously reported 68Ga labeled leptin derivative. The 
improved yield of the radiochemical synthesis for 68Ga-DOTA-leptin is likely due to the 
high stoichiometry of chelator to protein (4:1), when compared to the prior report (1:1)97. 
The synthesis of 68Ga-DOTA-leptin is highly optimized with respect to temperature, 
concentration of the protein, and time of reaction, and is not likely to improve. Thus, the 
only way to improve this tracer would be to start with more 68Ga. During the course of 
our experiments the 68Ge/68Ga generator produced 0.15-0.3 GBq of 68Ga, while generators 
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producing up to 3.7 GBq are commercially available. A 10-20 fold improvement in 
specific activity could easily be obtained by using such a generator. An alternate method 
would be to use 64Cu to label DOTA-leptin. This isotope has recently become popular 
owing to the high resolution of the images it generates (Bmax of 0.65 MeV, comparable 
to 0.63 MeV for 18F, see table 2)105. For example, a 64Cu labeled vascular endothelial 
growth factor (VEGF) derivative has recently been applied to PET imaging in various 
animal models194-197. The major drawback in the use of this isotope is the half-life of 12.8 
hours and the low percentage of positrons it emits (18%), which results in a high 




Ref Protein Chelator Yield (%) 
Specific 
activity Note 
198 Antibody DTPA N.R. N.R.   
97 Leptin DTPA N.R. 1.7 - 6 GBq/μmol 3.7 GBq generator 





199 Albumin DOTA 45 11 GBq/μmol   
138 EGF DOTA N.R. 12-20 GBq-μmol 
90 degree microwave 
labeling 
Chapter 
2  Leptin DOTA 
25.7 
±  4.7 
5.5 - 11 
GBq/μmol 0.15 - 0.37 Gbq generator 
Table 5. A comparison of 68Ga-DOTA-leptin to previously reported 68Ga protein tracers. 
N.R. = not reported. 
 
 18F-FBA-leptin is compared to other 18F labeled proteins reported in the literature 
on Table 6, and Figure 35.  Our labeling method, based on expressed protein 
ligation144,200, is unique among the 18F labeling techniques in that it is intrinsically site-
specific and directed to the C-terminus163. Furthermore, the yields of the two reactions in 
our synthesis, the preparation of 18F-FBA and the aniline-accelerated oximation, are 
comparable to the best methods published. However, the specific activity of 18F-FBA-
leptin order of magnitude lower than the best prior reports of 18F-labeled proteins159,201,202. 
This is for three reasons: firstly, the reformulation of 18F-FBA into water is time 
consuming, and requires multiple handling steps. Furthermore, as our synthesis is 
manual, a relatively small amount of starting radioactivity can be used due to safety 
concerns. Finally, the recovered yield of our labeling reaction is relatively low owing to a 
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tendency of our labeled protein to precipitate. Finally, due to the tendency of leptin to 
precipitate, we must perform our labeling reaction on ice. Most prior 18F labeling 
reactions have been conducted at elevated temperatures, which accelerates the 
conjugation. Optimization of the synthesis along the lines of several previous reports 


















125 Albumin Amine 67 ± 15.7 25-90 N.R. N.R. 7 Manual 
203 Albumin Amine 50 - 60 90 N.R. N.R. 8 Manual 
124 Albumin Amine 50 N.R. 15 N.R. 9 Manual 
204 Annexin V Amine N.R. N.R. N.R. 0.02 - 0.033 8 Manual 
202 Annexin V Amine N.R. N.R. 15-20 35 8 Automated 
205 Annexin V Amine N.R. 70 17.6 ± 5.6 1.3 8 Manual 
206 Antibody Amine N.R. N.R. 39 11 8 Manual 
 207  Antibody Amine 25 50 N.R. N.R. 8 Manual 
208 Antibody Amine 30 - 35 15 - 20 3 3.7 - 40 8 Manual 
209 Antibody Amine 25 N.R. 0.5 12-17 8 Manual 
210 Antibody Amine N.R. 25 - 40 N.R. 18 10 Manual 
159 Epo Amine 16.5 19.8 ± 5.2 N.R. 147 8 Manual 
201 Transferrin Amine N.R. N.R. N.R. 37 - 74 8 Manual 




Leptin C-terminus 40 - 70 65 3 9.25 - 16.65 7 Manual 
                  
211 Affibody Cys 50-70 N.R. 13 - 18 10.4 - 20.8 7 Automated 
131 Annexin V Cys 45-69 43 - 58 N.R. 2 - 4 11 Manual 
132 Annexin V Cys 23 ± 4 37 ± 9 N.R. N.R. 12b Manual 
117 Ab fragment Cys 28-37 60-70 N.R. N.R. 12a Manual 
128  LDL Cys 29 17 ± 10 N.R. 50 - 300 12c Manual 
                  
212 MS2 phage Tyr 65 - 75 15 - 25 N.R. N.R. 7 Manual 




Figure 35. Previously described 18F-based synthons for protein labeling, referred to on 
table 7. 
 
 The synthesis of 18F-FBA-leptin could be improved in several ways. Firstly, 
automation of the synthesis of 18F-FBA, as previously reported211, would allow for an 
increase in starting radioactivity of up to five fold, since a limiting factor in the amount of 
radioactivity is the dose of radiation to the hands of the operator. In the labeling of 18F-
FBA-leptin, a paradoxical decrease of labeling efficiency was observed when increasing 
portions of the 18F-FBA product was added to aminooxy-leptin 4, suggesting that the 18F-
























































Consistent with this was the finding that intact aminooxy-leptin 4 was not observed in the 
radiochemical product of the labeling reaction, but instead only a mixture of products 
with a higher mass were found (data not shown). Therefore it is likely that the specific 
activity of the 18F-FBA is moderate and may represent the limiting factor in generating 
high specific activity leptin. Optimization of the purification conditions and 
reformulation of 18F-FBA, along the lines of a recent report132, would improve its specific 
activity. Another option would be to forgo the use of 18F-FBA altogether, and to instead 
use 18F-fluorodeoxyglucose (FDG). 18F-FDG is the most commonly used PET tracer, and 
a recent study revealed that it could be used to label small molecule substrates (e.g. 
compound 11, Figure 35) by oximation131. It is likely that using aniline to accelerate this 
reaction would render it useful for protein labeling. These improvements in the 
generation of the 18F synthon for leptin labeling would likely lead to an improved 
radiotracer. 
Finally, it is likely that altering the structure of the aminooxy-leptin used as a 
precursor would improve the stability of the labeled leptin. One simple method to 
accomplish this would be to dramatically shorten the linker length between the protein 
and the aminooxy group. For example, the length of the linker could be reduced from 29 
atoms (Scheme 1) to 2 atoms by expressed protein ligation with the reagent in Scheme 
5A. This compound could readily be synthesized from previously described N-[2-(tert-
butyl-N-hydroxycarbamoyl)ethyl]amine213 in two steps (Scheme 5B). This compound 
could be conjugated to leptin using expressed protein ligation, similar to the technique 
shown on Scheme 2. Based on experiments in which other small moieties were installed 
at the C-terminus of leptin (data not shown), the smaller linker would likely have greater 
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stability and bioactivity than the previously described 18F-FBA-leptin. Alternatively, the 
lysine-directed aminooxyacetic acid / 18F-FBA strategy (Section 2.5) could be further 
explored and applied to imaging in vivo. It is likely that implementing these 
improvements to both the protein chemistry and the radiochemistry would substantially 
increase the specific activity of the final tracer. In turn, the improved specific activity of 
these tracers could potentially allow for better visualization of high affinity, low capacity 
interactions of leptin, such as transport into the brain, by micro-PET imaging in mice. 
Furthermore, the optimization of the specific activity of the tracer is crucial for 
translation of the imaging methodologies to human subjects. 
 
 
Scheme 5. A) Structure of proposed short-aminooxy Cys-linker. B) Proposed synthesis 
for short aminooxy Cys-linker. 
 
 
5.2. Biodistribution results and discussion 
 Our study of leptin biodistribution represents the most extensive report to date. 
Van Heek et al. studied leptin biodistribution using 125I leptin; however doses of the 
hormone were used which saturate peripheral receptors (injected dose of 0.3 mg/kg)92. 
Nevertheless, they were able to observe leptin binding in the bone marrow. Karonen et al. 




































brain96. One study used 125I-leptin to study leptin transport across the placenta in 
pregnancy in rats214. In chickens, leptin has a very high level of uptake in the kidney, but 
also in the testes, lung, and spleen183. Several studies have used 125I-leptin to study the 
transport of leptin into the brain17,39,182,215,216. Collectively, these previous biodistribution 
studies have suffered from a lack of displacement studies using cold ligand, and no 
molecular characterization of binding sites has been performed. Thus, to date there is no 
comprehensive description of leptin biodistribution. 
Our results incorporate data from three different labeled molecules, 68Ga-DOTA-
leptin, 18F-FBA-leptin, and 125I-leptin, in model systems including mice, rats, and rhesus 
macaques. A comparison of our experiments reveals largely consistent results, when the 
effect of injected dose is considered (see Table 7). The different results obtained in 
micro-PET and ex vivo biodistribution experiments are likely the result of receptor 
saturation at both high affinity receptors (ObR) and low affinity receptors (megalin) and 
can be summed up as follows. In the case where a very small amount of tracer is injected, 
relative to the size of the animal, such as in ex vivo biodistribution studies using 125I-leptin 
and 68Ga-DOTA-leptin, and in PET imaging in rhesus macaques using 68Ga-DOTA-
leptin, there is no saturation of high affinity receptors. In intermediate cases, including 
micro-PET imaging in mice using 68Ga-DOTA-leptin and 18F-FBA-leptin, or PET 
imaging in rhesus macaques with a small amount of competing leptin, high affinity 
peripheral receptors are saturated (ObR). Thus, micro-PET imaging in mice has been 
useful principally for studying the low affinity interaction of leptin with megalin. The 
final case is biodistribution and PET imaging experiments in mice, where a high dose of 
competing leptin is co-injected, saturating both high affinity (ObR) and low affinity 
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receptors (megalin). Collectively, our biodistribution and PET results suggest that 
megalin is a low affinity receptor for leptin in the kidney, and ObR is a high affinity 
receptor for leptin in the bone marrow, lung, liver, fat, spleen, and brain.   
 





















dose <100 ng 
20-30 








<0.003 0.66-1 22 0.12 0.006 0.1 
Table 7. Summary of effective doses delivered in different animal experiments 
performed in this thesis. 
 
 The uptake of leptin in the kidney by megalin is discussed in section 5.3, the 
uptake in the spleen and bone marrow by ObR is discussed in section 5.4, and in the brain 
in section 5.5. Our biodistribution results in mice and PET imaging in rhesus macaques 
also reveal uptake of leptin in the lung, liver, and fat. Although ObR mRNA is found in 
both lung and liver, its physiologic effects in these tissues remains unclear. ObRb is 
abundantly expressed in the lung37, while the short isoforms (ObRa, c, and f) are more 
abundantly expressed in the liver217. The role of leptin in the physiology of the lung is 
less clear than in other organs. It is possible that our data represent binding to resident 
immune cells of the lung, as leptin receptor positive T-cells are present in large numbers 
in this organ218. Dal farra et al also found that leptin binding sites are present in the 
 109 
pulmonary parenchyma as well as bronchiolar epithelium83. It is likely that these cells are 
the ones that leptin is bound to in our study.  
The relatively low uptake of leptin in the liver compared to other organs (4.1 ± 
0.1% ID/g for liver vs. 24.8 ± 4.0% ID/g for spleen in mice) suggests that leptin may only 
bind to a subset of cells in the liver, or that liver cells expressed relatively little ObR. 
Leptin induces IRS-1 phosphorylation in cultured HEP-G2 hepatocytes, in a manner that 
mimics insulin signaling219-221. However, a tissue specific knockout of leptin receptor in 
hepatocytes resulted in no apparent metabolic phenotype, revealing that this effect is not 
required for normal glucose homeostasis18. Leptin also has a direct effect on hepatic 
stellate cells, inducing collagen production and promoting fibrosis222. One study 
suggested that leptin receptor in the liver was induced by both leptin treatment and short-
term starvation. In particular, ObRe production was enhanced, suggesting that the liver 
may act as a reservoir of the circulating leptin receptor223. Thus, while our results 
showing leptin:ObR binding in the lung and liver are consistent with mRNA expression 
data in mice, the physiological effect of leptin in these tissues remains unknown. The 
identification of which cell types leptin is binding to in the lung and liver could provide a 
starting point for identifying the physiological role of leptin in these tissues. 
 We also found saturable uptake of leptin in the fat of Ob, but not wild type mice 
(Table 3b). This suggests either that these receptors are saturated under physiological 
conditions, or that hypoleptinemic animals such as Ob mice upregulate ObR. The role of 
ObR in the fat tissue is currently obscure. Some experiments have suggested that the 
action of ObR is required for full lipolysis to take place in the tissue71,72. Our finding, that 
there is no saturable uptake of leptin in fat tissue in normal wild type mice, suggests that 
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the ObR receptor on fat may play a role in fasting or starving conditions. For example, 
under conditions of starvation, a lack of ObR signaling on adipocytes could act to alter 
the metabolism of the adipocytes. As a first step in evaluating this hypothesis, the uptake 
of 125I-leptin adipose tissue in fasted wild type mice and rats could be evaluated and 
compared to well fed animals. 
 
5.3 Leptin and megalin in the kidney, and potential implications of the 
megalin:leptin interaction 
Our study is the first, to our knowledge, to utilize PET to systematically 
investigate leptin biodistribution in the kidney. We found a similar biodistribution 
pattern, in which leptin is taken up in the cortex of the kidney, in mice, rats, and rhesus 
macaques (Figure 20). In both humans and rodents, leptin has a short half-life, and 
kidneys are the major site of leptin metabolism from the circulation, accounting for over 
80% of all clearance from plasma12,84,87,88. The half-life of leptin appears to be unaffected 
in ob/ob, db/db, or mice on a high fat diet92,224. Our finding of rapid and identical kidney 
uptake in ob/ob, ObRΔ/ob/ob, and wild type mice, with approximately 50% of the total 
hormone appearing in the kidney 3 min post injection, is consistent with these studies 
(Figure 24a).  End stage renal disease (ESRD) causes increased leptin levels164 and this 
increase could underlie the induction of anorexia, a symptom associated with ESRD225. 
Thus, the clearance of potent low molecular weight hormones such as leptin by the 
kidney is a problem of clinical significance. 
 Several studies have shown that leptin metabolism in the kidney is the result of an 
active process165. Conflicting reports suggested that leptin uptake in the kidney is 
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saturable84 or non saturable158. The evidence that both the long (ObRb) and one of the 
short (ObRa) isoforms of leptin receptor are expressed mainly at the loop of Henle50 in 
the kidney, and are capable of mediating internalization of leptin in vitro93, makes them 
candidate leptin transporters in that organ. ObRb may also mediate a possible natriuretic 
effect of leptin226. In vitro binding experiments performed with 125I-leptin on kidney 
preparations have shown binding exclusively at the level of the medulla, which could be 
compatible with ObR distribution81.  
However, we have presented several lines of evidence that unequivocally 
demonstrate that megalin (gp330/LRP2), and not ObR, is required for leptin metabolism 
in the kidney in vivo. Our results in 3 different mammalian species (mouse, rat, and 
rhesus macaques) show that leptin is actively taken up in the renal cortex, which is not 
compatible with the aforementioned pattern of leptin receptor expression.  Furthermore, 
leptin uptake in the kidney was not significantly reduced in ObRΔ animals, which lack 
leptin receptor. Recently, Hama et al. found that megalin (gp330/LRP 2) binds leptin with 
an apparent affinity of 300 nM in QCM analysis and can mediate leptin uptake in an L2 
yolk sac tumor cell line50. Megalin is highly expressed at the proximal convoluted tubule 
in the kidney cortex. It is involved in endocytosis of several ligands, including hormones 
and their precursors (PTH, insulin, prolactin, EGF, thyroglobulin) vitamin binding 
proteins (Vitamin-D binding protein, retinol binding protein, transcobalamin-VitB12) and 
carrier proteins (Haemoglobin, myoglobin, albumin, lactoferrin, transthyretin)50,167. 
Megalin knockout mice are severely compromised due to a deficit in the development of 
the forebrain (holoprosencephaly) and die perinatally227. Megalin kidney specific 
knockout mice (megalinlox/lox, ApoEcre) show a normal phenotype but reduced kidney 
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uptake of several megalin ligands175,228,229. We have demonstrated that megalinlox/lox, 
ApoEcre eliminate leptin in the urine (Figure 25). This finding was confirmed using 
micro-PET imaging (Figure 26). Thus, megalin, and not ObR, is required for the uptake 
and degradation of leptin in the kidney following filtration of the protein at the 
glomerulus.    
To our knowledge, this is the first report of a non-ObR cell surface receptor 
playing a role in leptin physiology. Our results have broader implications since megalin is 
expressed in several organs such as lung, intestine, thyroid, parathyroid, placenta, 
endometrium, yolk sac, testicle, ovary and in brain microvessels and choroid plexus230, 
anatomical structures that are part of the blood brain barrier that leptin actively crosses to 
enter in the brain167. For example, our findings support the need for intensive 
investigation on the interaction between leptin and megalin at the blood brain barrier174. 
We speculate that megalin mediated uptake and transport of leptin in different tissues and 
organs could become a target for pharmacological intervention useful for the treatment of 
obese patients. 
 
5.4 Leptin in hematopoiesis 
 Our biodistribution results support the idea that leptin plays a significant role in 
hematopoiesis and immunity in mammals. In mice, leptin binds to bone marrow and 
spleen, in an ObR dependant manner (Table 3a, Figure 28). One previous biodistribution 
study also found uptake of 125I-leptin in the bone marrow92. By PET imaging using 68Ga-
DOTA-leptin in rats, leptin localized to the proximal femur, a site of bone marrow 
production in rodents (fig 19). In rhesus macaques, binding to the spleen is very low, 
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while uptake in bone marrow is high (16% of total injected dose, Figures 33-34). These 
results are consistent with binding of leptin to tissues undergoing active hematopoiesis: in 
mice, spleen and bone marrow are sites of hematopoiesis, while in adult rhesus macaques 
and humans only the bone marrow is193. An ex vivo tissue section binding study found 
high affinity binding sites using 125I-leptin in the fetal liver in mice, which decrease 
during development, as binding in the spleen increases83. This pattern of receptor 
distribution follows the development of hematopoietic tissues in mice, where the liver 
serves as the sites of hematopoiesis in utero, while the spleen and bone marrow serve this 
function in adult mice. Thus, taken together with the previous data, leptin binds to sites of 
active hematopoiesis, in an ObR dependant manner, in mice, rats, and rhesus macaques. 
 Several lines of evidence support an important role for leptin in regulating 
hematopoiesis and immune function231,232. Firstly, humans lacking a functional leptin 
gene are predisposed to frequent upper respiratory tract infections, and have reduced 
CD4+ T-cells. Furthermore, lymphocytes isolated from these patients have reduced 
proliferative responses, and dysregulated cytokine production consistent with an excess 
of Th2/regulatory cytokines. This abnormal phenotype is corrected by treatment with 
recombinant leptin21. A similar syndrome is seen in ob and db mice, which have severely 
impaired humoral and cell-mediated immunity233,234. Ob mice have substantially reduced 
lymphopoiesis, particularly in the B-cell compartment, which is corrected by leptin 
treatment235. Furthermore, Ob mice are protected against experimental autoimmune 
encephalitis69. Thus, leptin is clearly required for normal immune function in humans and 
rodents. 
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Leptin also has effects on hematopoietic stem cells and mature immune cells in 
vitro. Leptin  stimulates proliferation and granulocyte-macrophage colony formation in 
hematopoietic stem cells in vitro236. Leptin receptors are abundantly expressed by 
hematopoietic stem cells, and marrow isolated from db mice has a blunted response to 
leptin treatment63,237. Furthermore, leptin has clear effects on immune cells in vitro: it 
promotes the secretion of pro-inflammatory Th1 cytokines (such as IFN-γ) at the expense 
of Th2 cytokines (such as IL-4), and it substantially increases the proliferation of naïve 
T-cells62. Additionally, leptin activates monocytes, augmenting the release of Th1 
cytokines238. Taken together, these data indicate that leptin plays a role in augmenting 
hematopoiesis (particularly lymphopoiesis) and plays a permissive role in immunity. 
 An interesting question raised by our biodistribution results is to what extent 
leptin is moderating the physiology of hematopoiesis and immunity directly, via receptors 
on bone marrow and mature immune cells. Our finding of extensive uptake of leptin in 
hematopoietic tissues in mice, rats and rhesus macaques, combined with ample evidence 
of leptin’s effects on immune and hematopoietic cells in vitro62,236-239, suggests that a key 
role of leptin in augmenting hematopoiesis and immunity is a direct effect on the 
hematopoietic cells. However, lethally irradiated db mice, with a wild type bone marrow 
transplant were unable to reconstitute a normal immune system, while db to wild type 
bone marrow chimeras had an essentially normal immune system240. These results 
suggest that the immune deficiency seen in db mice is not intrinsic to immune cells, but 
rather that it is due to a deficiency in either the bone marrow microenvironment or 
elsewhere in the organism. However, these results must be interpreted with caution, as 
the lethal irradiation technique does not completely destroy the host immune system, and 
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the degree of chimerism in these experiments is only 80%. Thus, it is possible that the 
remaining 20% of wild type immune cells mask the immune deficit. Furthermore, leptin 
can still induce granulocyte-macrophage colony formation, albeit to a lesser extent, in 
marrow isolated from db mice236. Thus, it is possible that leptin may still function via the 
truncated ObR16 in db mouse marrow, or that it may act via an alternative mechanism in 
these cells. One potential approach to overcome these limitations would be to use 
lymphocyte specific promoters241 to knock out ObR in specific hematopoietic tissues, or 
alternatively to drive ObRb expression in these tissues in mice lacking all isoforms of the 
leptin receptor. Thus, to date the relative contribution of leptin signaling to immune 
function via direct action on blood cells and precursors, versus indirect actions via other 
tissues, has not been fully addressed. 
 A second question raised by our study is which cell types leptin is binding to in 
the bone marrow. This question was partially addressed by Gainsford et al., who 
incubated a human bone marrow preparation with 125I leptin in vitro, and then 
characterized which cell types took up the tracer by autoradiography239. In this assay, a 
variety of precursors, including blasts, myelocyte precursors, promonocytes, and 
monocytes took up the tracer. Only a small subset of lymphocytes took up the tracer, and 
some of these had “intense labeling.” These results imply that leptin has different effects 
on different lymphocyte populations. A molecular characterization of leptin-binding to 
immune and hematopoietic cells using cell-specific antigens has not been performed to 
date. It is likely that the question of the specific substrates of leptin action in 
hematopoietic and immune tissues could be answered by flow cytometry using 
fluorescently labeled leptin in combination with cell-type specific antibodies. 
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 A final intriguing possibility raised by our finding of intense uptake of leptin in 
the bone marrow is the possibility of using this tracer as a diagnostic imaging agent. In 
humans, leptin receptor is overexpressed in a subset of patients with acute myelogenous 
leukemia (AML), chronic myelogenous leukemia (CML) and in acute promyelocytic 
leukemia (APL)242-244. Leptin receptor is also expressed in solid tumors, including 
endometrial245, hepatocellular,246 breast,247-249 colorectal,250 and renal251 cancers. Leptin 
receptor is being actively investigated as a marker for these cancers249,251,252, and it is 
likely that using the tracers 68Ga-DOTA-leptin and 18F-FBA-leptin as an imaging agent in 
patients with these tumors could aid in visualizing, staging, and diagnosing these 
malignancies. 
 
Section 5.5 Leptin transport into the brain 
We found that uptake of leptin in the brain occurs at extremely low levels, with 
uptake values of between 0.1 to 0.4% of injected dose per gram of tissue in mice (Table 
3A). These results are consistent with previous reports of leptin transport into the 
brain17,92. These experiments reveal that leptin is taken up in the brain in a saturable 
manner in an ObR dependant manner. To our knowledge, these results represent the first 
conclusive report that leptin uptake in the brain is dependant on ObR in vivo, as all 
previous experiments used ObR-deficient mice with high circulating levels of leptin, 
which would saturate any binding sites.  
One possibility is that ObR itself mediates the transport of leptin across the BBB, 
as ObRa is abundantly expressed on choroid plexus and cerebral microvessels39. 
However, Banks et al. found no difference in the transport of leptin across the BBB in a 
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perfusion model in the Koletsky rat, which lacks functional leptin receptors 
altogether40,253. In this model, the brain is perfused with a saline solution containing 
leptin, and thusly corrects for serum components interfering with leptin brain transport. In 
contrast, Hileman et al found that mice lacking ObR had reduced transport of the protein 
in a similar brain perfusion system39.  Thus, although the suggestion that ObR mediates 
the transport across the BBB is over a decade old, it has not been conclusively proven or 
disproven. 
An intriguing question raised by our experiments and that of others is the relative 
role of megalin in the transport of leptin into the brain. A recent report showed that a 
transfection of a virus expressing siRNA directed against megalin reduced transport of 
leptin into the brain in mice174. Based on these results, the authors concluded that megalin 
mediates the transport of leptin into the CSF. These results are supported by our own 
finding that megalin mediates the uptake of leptin in the kidney. It is possible that either 
or both ObR and megalin mediate the transport of leptin into the brain, or that there is 
cross-talk between these systems. Furthermore, Banks et al. have suggested that there are 
two mechanisms of transport into the brain, a saturable and a non saturable one, and that 
transport varied in different regions of the brain182. Similarly, Thomas et al. found a 
saturable and non-saturable component of leptin transport into the CSF in a sheep choroid 
plexus model216. The molecular identity of these transporters remains obscure. 
Nevertheless, it is likely that either megalin or ObR, or both acting together, play a role in 
this mechanism. Animals with deletions of these receptors in the choroid plexus and 
capillary endothelium could be used to evaluate this hypothesis. 
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Chapter 6. Materials and methods 
 
General Methods 
Amino acid derivatives, resin and coupling reagents were purchased from Novabiochem 
(San Diego, CA) unless otherwise indicated. Boc-aminooxyacetic acid was purchased 
from Sigma-Aldrich (Milwaukee, WI). All other chemicals were purchased from Sigma-
Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). Recombinant murine 
leptin was a gift of Amgen (Thousand Oaks, CA), or Amylin (San Diego, CA). 
Analytical gradient reversed phase HPLC was performed on a Hewlett Packard 1100 
series instrument and a Vydac C18 or C4 column (5 micron, 4 X 150 mm). Flow rate was 
1 mL/min and detection was at 214 and 280 nm. Preparative scale HPLC was performed 
on a Waters Delta Prep 4000 fitted with a Waters 486 tunable absorbance detector and 
using either a Vydac C4 process scale column (5 x 25 cm) at 30 mL/min, a Vydac C18 
process scale column (5 x 25 cm) at 30 mL/min, or a Vydac C4 semiprep scale column (1 
x 25 cm) at 5 mL/min. Radiochemical HPLC was performed on a Varian ProStar series 
instrument fitted with a model 320 UV detector and a Bioscan flowcount radiodetector 
(Bioscan Inc., Washington D.C.), and either a Vydac analytical C4 column (5 micron, 4 
X 150 mm) at 1 mL/minute or a Waters μBondapak C18 (7.8 x 300 mm) column at 3 
mL/min as indicated. HPLC mobile phase buffers A and B were 0.1% trifluoroacetic acid 
in water, and 90% acetonitrile, 0.1% trifluoroacetic acid in water, respectively. 
Electrospray mass spectrometry was routinely used on all peptides and proteins, using a 
Sciex API-100 single quadrapole spectrometer. Thin layer chromatographic (TLC) 
analysis was conducted using normal phase silica 60, F254, 250 μm, 2.5 x 7.5 cm plates 
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(Spectrum Chemical, Gardena, CA). Quantification of radiochemical thin layer 
chromatography plates was performed on a Bioscan Mini-Scan TLC scanner (Bioscan, 
Washington, D.C.). All enzymes involved in the construction of the plasmids were 
obtained from New England Biolabs (Ipswich, MA). All molecular biology kits were 
obtained from Qiagen unless otherwise specified. Metal free buffers were prepared by 
pre-treatment of the buffers with Chelex 100 resin (Biorad, Hercules, CA). 
 
Animal Maintenance 
Wild type C57BL/6J and Ob/ob mice were obtained from Jackson laboratory (Bar 
Harbor, ME). Megalinlox/lox, ApoEcre  and megalinlox/lox mice were obtained from Dr. T. 
Willnow (Max-Delbrueck Molecular Cardiovascular Research and Medical Faculty, Free 
University of Berlin175.) Rats used for PET scans were male Sprague-Dawley purchased 
from Charles River Laboratories. ObRΔ/ob/ob mice were generated in our laboratory 
crossing heterozygote mice for both the leptin receptor mutation (ObRΔ18) and leptin 
gene mutation (ob). All mice were maintained in cages in temperature controlled rooms. 
All animals were subjected to a 12 h light/dark cycle. Procedures and measurements were 
performed between 10:00 and 17:00 hours. Animal care and experiments were conducted 
in accordance with approved guidelines of The Rockefeller University. 
Rhesus macaque subjects were two gonadally intact adult male rhesus monkeys 
(Macaca mulatta). Subjects were approximately 14 years of age and weighed in the range 
10-12 kg. Subjects were housed in a stable colony and were previously exposed to the 




Titration of leptin labeling with DOTA-NHS 
Murine leptin (Amgen/Amylin) at 13.1 mg/mL was diluted to 5 mg/mL using 100 
mM metal free sodium phosphate pH 7.0. To 10 µL of the resulting solution was added 2 
µL of 10 mg/mL DOTA-NHS (Macrocyclics Inc., 40 nmol, 5 equivalents), or 4 µL 10 
mg/mL DOTA-NHS (80 nmol, 10 equivalents). Additionally, to 262 µL of the same 
solution was added 100 equivalents of DOTA-NHS (8.2 µmol, 4.12 mg), and the pH was 
adjusted to 7.5 with metal free 1N NaOH. The reactions were allowed to proceed 1-3 
hours at 4 degrees, and then analyzed by C4 RP-HPLC on a 0-100% B gradient, and by 
ESI-MS. 
 
Preparation of DOTA-leptin 
 A lysine-directed labeling approach using DOTA-NHS ester (Macrocyclics) was 
employed. Briefly, to 100 µL mouse leptin solution at 13.1 mg/mL (Amylin) was added 
162 µL metal free (by chelex resin treatment, Biorad) 100 mM sodium phosphate pH 7.5 
(final concentration of 5 mg/mL). To this solution was as added 100 equivalents of 
DOTA-NHS (8.2 µmol, 4.1 mg), and the pH adjusted to 7.5 using 1N NaOH. The 
reaction proceeded for 3 h at 4 °C at which point it was purified by HPLC using a 
Hewlett Packard 1100 series instrument and a Vydac C4 column (5 micron, 4 X 150 mm) 
on a 45-60%B gradient (where buffer A is 0.1% trifluoroacetic acid in water, and buffer 
B is 90% acetonitrile, 0.1% trifluoroacetic acid in water.) The product was characterized 
by ESI-MS on a Sciex API-100 single quadrapole spectrometer, which indicated the 
incorporation of 2-6 DOTA moieties per leptin molecule. The solution was separated to 8 
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aliquots of DOTA-leptin and lyophilized.  
 
Generation of a Stable Cell Line Overexpressing Leptin Receptor Long Isoform 
(Ob-Rb) and a Stat3-Responsive Element-Luciferase Reporter 
A stable Flp-In 293 cell line254 expressing the long isoform of the leptin receptor 
(Ob-Rb) that is capable of full signaling (kind donation of Dr. Cai Li, University of Texas 
Southwestern) was stably transfected with a p4xm67 luciferase plasmid, containing a 
STAT3 responsive element and luciferase DNA (kindly provided by Dr Jim Darnell, The 
Rockefeller University). Cells were transfected with p4xm67 luciferase and a puromicin 
resistance plasmid following the Lipofectamine 2000 method (Invitrogen). Stable 
integrants were selected in Dulbecco’s modified Eagle’s medium containing 10% fetal 
bovine serum and puromicin (1.5 μg/ml) for about 4 weeks. Single cell clones were then 
selected for leptin induced luciferase production and the clone with the best response to 
leptin used for further experiments. 
 
Luciferase Reporter Assay of Leptin Receptor Activation  
Ob-Rb-STAT3-luciferase cells were seeded into 24-well plates. At a confluence 
of 80% the cells were washed and replaced with serum-free medium. After 4 hours the 
medium was changed and replaced by serum-free medium containing dilutions of leptin 
or the appropriate semisynthetic derivative. Samples were assayed in duplicate for every 
dilution. After 24 hours cells were collected and luciferase activity measured in cell 
lysate using a luciferase assay system (Promega). 
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Leptin Administration to ob/ob Mice 
Leptin or its semisynthetic derivatives were administered continuously with mini 
osmotic pumps (Alzet, Cupertino, CA, model 2002) to Ob/ob mice with an exchange rate 
of 450 ng/h for ob/ob mice. Pumps were filled aseptically according to the manufacturer 
instructions with either sterile PBS solution, leptin, or leptin derivatives. Recombinant 
leptin or leptin derivatives were diluted in sterile PBS buffer. Before surgery, pumps 
were incubated overnight in a sterile 0.9 % NaCl solution at 37 °C to achieve immediate 
and constant pumping rate at the time of implantation. During surgery mice were 
anesthetized with isofluorane. Pumps were implanted subcutaneously in the interscapular 
region of the mice. Body weight was measured on a daily basis following surgery. 
 
68Ga labeling of DOTA-leptin. 
One DOTA-leptin aliquot consisting of approximately 70-100 µg of protein (see 
above) was resuspended in 40 µL of metal free 15 mM HCl. After incubation for 10 
minutes on ice to allow full resuspension of the protein, 10 µL of 1.2M sodium acetate 
(pH 4.5) was added. Immediately prior to addition of the 68Ga solution, the protein 
solution was centrifuged for 2 minutes at 10,000 x g to remove insoluble components. 
DOTA-leptin was labeled using 68Ga eluted from a 68Ge generator (Isotope 
Products Laboratories) using a previously described procedure199 with modifications. We 
found that reproducible labeling results were obtained by eluting the generator the 
evening prior to labeling, presumably to remove impurities. The gallium generator was 
eluted with 7 mL of 1M metal free HCl. The solution was diluted with 7 mL of 
concentrated HCl (trace metal grade, Fisher), and applied to 150 µL settled volume of 
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AG1-X8 resin (Biorad). The 68Ga was then eluted from the resin using 300 µL 15 mM 
HCl and followed by 100 µL of 15 mM HCl. The dilute acid solution was evaporated at 
160 degrees, and the 68Ga was subsequently resuspended in 40 µL of metal free 15 mM 
HCl. The 68Ga solution was then added to the leptin-DOTA solution (above), and 
incubated in a 35 °C water bath for 20 minutes. The solution was then centrifuged for 1 
min at 10,000 x g, and the supernatant added to 2 µL of 0.1M 
diethylenetriaminepentaacetic acid (DTPA). After 2 min the solution was transferred to a 
micro bio-spin P6 column (Biorad), which had been pre-equilibrated with PBS according 
to the manufacturer’s instructions. The 68Ga -DOTA-leptin was eluted from the column 
by centrifuging at 1000 x g for 4 minutes. Following elution the solution was diluted to 
an appropriate volume for injection in PBS (typically to 0.5-1 mL), and filtered through a 
0.22 µm filter. The specific activity of the conjugate at the end of synthesis was 9.1 ± 4.2 
GBq/µmol (s.d., n = 30 syntheses) at greater than 90% pure as determined by 
radiochemical HPLC and iTLC. The amount of total protein in the reaction was 
determined by BCA assay (Pierce). 
 
Radiochemical HPLC and iTLC analysis 
 Radiochemical HPLC was performed on a Varian ProStar series instrument fitted 
with a model 320 UV detector and a Bioscan flowcount radiodetector (Bioscan Inc., 
Washington D.C.), and a Vydac analytical C4 column (5 micron, 4 X 150 mm) at 1 
mL/minute. HPLC mobile phase buffers A and B were 0.1% trifluoroacetic acid in water, 
and 90% acetonitrile, 0.1% trifluoroacetic acid in water, respectively. Linear gradients 
from 0-100%B over 30 minutes with a 2 minute isocratic were used.  
 124 
 iTLC was performed using ITLC SG silica impregnated glass fiber sheets (Pall, 
East Hill, NY), with 5 mM diethylenetriaminepentaacetic acid (DTPA) as an eluant. 
Quantification of radiochemical thin layer chromatography plates was performed on a 
Bioscan Mini-Scan TLC scanner (Bioscan, Washington, D.C.). 
 
Stability of 18F-FBA-leptin 5 and 68Ga-DOTA-leptin in vivo 
Approximately 20 MBq of 18F-FBA-leptin 5 or 68Ga-DOTA-leptin was injected 
into either ob/ob or wild type mice via the tail vein. After 20 - 30 minutes (as indicated in 
the text), the animals were sacrificed and 500 μL of whole blood was collected. The 
blood was centrifuged for 15 minutes at 7000 rpm, and the supernatant injected on a C4 
analytical HPLC.  
 
Radioactive Cell Binding Experiment 
ObRb expressing cells were grown overnight in suspension in Dulbecco’s 
modified Eagle’s medium containing 10% fetal bovine serum at 37 °C and 5% CO2. Cell 
viability and concentration was then determined using trypan blue staining. Cells were 
washed with serum free medium and re-suspended in HBSS supplemented with 0.1% 
BSA at a final concentration of 20 million/mL. For each cell binding assay, 750 μL of 
cell suspension was incubated with a constant amount of radiolabeled leptin 
corresponding to 80,000 cpm of radioactivity (either 68Ga-DOTA-leptin or 18F-FBA-
leptin) + 60 μg of cold leptin. The concentration of the labeled leptin was determined 
using the BCA method (BCA protein Assay Kit, microplate procedure, Pierce). 
Following incubation of the cells at room temperature for 2 hours at constant agitation, 
the cell suspension was washed twice with 0.5 mL of HBSS with 0.1% BSA and 
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centrifuged at 2000 rpm for 5 minutes. The radioactivity associated with cell pellet (cell 
bound activity) was determined by counting the tubes in a gamma counter with 
corresponding standards and blanks. 
 
Cloning of Leptin(1-146)-GyrA-His6  
The sequence encoding the chitin binding domain in the pTXB vector (New 
England Biolabs, Ipswich, MA) was replaced with a His6 tag sequence to facilitate 
protein purification under denaturing conditions. Synthetic oligonucleotides encoding a 
His6 tag flanked by AgeI and PstI restriction sites (sense strand; 5’-
CCGGTGGAGCGCATCATCATCATCATCATGGAGCGTAACTGCA and antisense 
strand; 3’-GTTACGCTCCATGATGATGATGATGATGCGCTCCA) were 
phosphorylated using T4 DNA kinase and annealed. The pTXB vector was digested with 
AgeI and PstI, and the annealed His-oligos inserted using T4 ligase to give plasmid 
pGyrAHis, the identity of which was verified by sequencing. cDNA encoding leptin(1-
146) was amplified by PCR from a leptin-EGFP plasmid (obtained from A. Zeigerer, 
Friedman lab) using forward and reverse primers 
(GGAATTCCATATGGTGCCTATCCAGAAAGTCCAGG 
and GGACTAGTGCATCTCCCGTGATGCATTCAGGGCTAACATCCAACTG, 
respectively) encoding the NdeI and SpeI restriction sites. The PCR product was purified 
by gel extraction and ligated into the pre-digested pGyrAHis plasmid using T4 ligase to 




Overexpression and purification of Leptin(1-146)-GyrA-His6  
E. coli BL21(DE3) cells (Novagen, Darmstadt, Germany) were transformed using 
the plasmid pLeptin-GyrA. Cells were grown to an OD600 of 15-25 in a Bioflo 3000 
Batch/Continuous bioreactor (New Brunswick Scientific, Edison, NJ) in superbroth 
media (Qbiogene, Irvine, CA) with 50 μg/mL ampicillin. The culture medium was 
supplemented with oxygen to keep oxygen gas levels constant at 30% and agitated at 350 
RPM. The pH was maintained at 7.0 automatically using 5N sodium hydroxide. The 
culture medium was supplemented with 2 mL/min 50% glucose and 2 mL/min 3X 
superbroth solution during growth. Overexpression was induced with 1 mM IPTG, and 
the flow of glucose and superbroth was increased up to 10 mL/min. After four hours of 
induction at 37 °C, the cells were harvested by centrifugation. Using this protocol 200-
250g of biomass was typically obtained per culture prep. 
 The cells were resuspended in lysis buffer consisting of 1% triton, 50 mM sodium 
phosphate buffer, pH 7.0, 200 mM sodium chloride supplemented with one complete 
protease inhibitor tablet, EDTA free (Roche, Basel, Switzerland) per 50 mL of buffer. 
The cells were lysed by passage through a French Press (Emulsiflex C5 homogenizer, 
Avestin, Ottawa, Canada.). The inclusion bodies were separated by centrifugation at 
16,000 rpm for 30 minutes, and subsequently resuspended overnight in one volume 
(relative to the cell pellet) of resuspension buffer consisting of 8 M urea, 20 mM 
imidazole, 150 mM sodium chloride, 100 mM sodium phosphate, pH 7.5. This 
suspension was centrifuged again at 16,000 RPM for 30 minutes to remove insoluble 
debris, and applied to 100 mL of Ni-NTA beads which were pre-equilibrated with 
resuspension buffer supplemented with 20 mM imidazole. The beads were then washed 
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with resuspension buffer supplemented with 20 mM imidazole, and the fusion protein 
was eluted from the column with 10 x 50 mL fractions of resuspension buffer 
supplemented with 500 mM imidazole. The fractions were analyzed by SDS-PAGE and 
those containing the 39 kDa fusion protein were pooled. 
 
Optimization of intein cleavage 
 100 μL of pure leptin-GyrA-His6 was refolded by dialysis overnight using four 
buffer changes of 250 mL, in buffer containing 200 mM sodium phosphate, 200 mM 
NaCl, 5 mM EDTA, pH 7.0, in the presence of varying additives, including 1 & 2M 
guanidine, and 2, 3, 4 and 5M Urea. Following dialysis, ethanethiol was added to 3%, 
and the samples were cleaved overnight at room temperature or at 4° C. Samples were 
analyzed by SDS-PAGE and Coomassie staining. 
 
Generation of Leptin(1-146) α-thioester, 1  
The combined Leptin(1-146)-GyrA-His6 fractions were refolded by extensive dialysis 
against 4 M urea, 100 mM sodium phosphate, 150 mM sodium chloride pH 7.0 at 4 °C. 
The first dialysis buffer was further supplemented with 10 mM EDTA to remove trace 
amounts of contaminating nickel. Intein cleavage to form the leptin (1-146) α-thioester 1 
was initiated by adding sodium 2-mercaptoethane sulfonate to a final concentration of 
100 mM. Cleavage was allowed to proceed for 2 days at 4 °C. The crude cleavage 
reaction was reapplied to 100 mL of nickel-NTA beads, which were pre-equilibrated with 
dialysis buffer supplemented with 20 mM imidazole. The beads were washed with 
dialysis buffer supplemented with 20 mM imidazole and 100 mM sodium 2-
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mercaptoethane sulfonate. The pooled flowthrough and washes from the Ni-NTA column 
containing principally the leptin(1-146) α-thioester 1 were then purified by process scale 
C4 RP-HPLC using a gradient of 50-65% buffer B. Fractions were analyzed by analytical 
RP-HPLC and ESI-MS, and those containing pure leptin α-thioester 1 were pooled and 
lyophilized. Residual uncleaved fusion protein on the Ni-NTA column could be 
recovered from the column by elution with 8 M urea, 500 mM imidazole, 500 mM 
sodium chloride, 100 mM sodium phosphate pH 7.0, and refolded and recleaved as 
above. Using this procedure, ~60 mg of pure leptin(1-146) a-α-thioester 1 could be 
obtained from an initial 5L culture. 
 
 
Synthesis of native murine leptin by EPL 
Leptin-GyrA-His6 was expressed, purified, and refolded as indicated above. EPL 
with cysteine was initiated using 100 mM sodium 2-mercaptoethanesulfonate and 10 mM 
cysteine, and the reaction was allowed to proceed for 3 days at 4 °C. After the reaction 
was complete, it was diluted to 0.25 mg/mL in 6 M guanidine hydrochloride, 20 mM tris 
pH 7.4, 5 mM dithiothreitol. The product was then dialyzed at 4 °C sequentially against 6 
M urea, 2.5 mM dithiothreitol, 2.5 mM 2-mercaptoethanol, 20 mM tris pH 7.4, then 
against 4 and 2 M urea containing 5 mM 2-mercaptoethanol, 20 mM tris pH 7.4, then 
against 20 mM tris pH 7.4, and finally overnight against 20 mM tris pH 7.4, 5 mM 
oxidized glutathione, 0.5 mM reduced glutathione, 150 mM sodium chloride. The crude 
refolded mixture was purified on a C4 semiprep RP-HPLC column using a gradient of 
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45-60% buffer B (buffer A = 0.1% TFA in water, buffer B = 90% acetonitrile, 0.1% TFA 
in water.) Fractions containing pure murine leptin were pooled and lyophilized. 
 
Synthesis of Peptide 2 
The peptide was prepared using manual Fmoc-based solid phase peptide 
synthesis, as indicated on Scheme 3. Agitation was achieved using a flow of nitrogen gas. 
Fmoc deprotection was achieved using 5 mL of 20% piperidine in DMF for 3 minutes 
followed by another treatment for 10 minutes. The resin was acetylated after every 
coupling using 5 mL of 10% acetic anhydride, 10% diisopropylethylamine (DIEA) in 
DMF for 10 minutes. Washes with DMF were performed in between all coupling, 
acetylation, and deprotection steps. 
 Fmoc-Lys(ivDde) (0.379 g, 0.66 mmoles) was coupled to Rink amide AM resin 
(420 mg, 0.71 mmol/g) using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU, 0.228 g, 0.6 mmoles), 0.5 mL DIEA, in 4 mL DMF for two 
hours. After capping and deprotection, Fmoc-NH-PEG2(20 atoms)-COOH linker (0.2 g, 
0.36 mmoles) was coupled to the resin using HBTU (0.125 g, 0.33 mmoles), 0.5 mL 
DIEA in 4 mL DMF for two hours. The coupling reaction was repeated. Following 
capping and deprotection, Boc-Cys(Trt)-OH (1.02 g, 2.2 mmoles) was coupled using 
diisopropylcarbodiimide (310 μL, 2 mmoles), N-hydroxybenzotriazole (0.270 g, 2 
mmoles) for 20 minutes. The coupling was then repeated. The ivDde group was 
deprotected using 2% hydrazine in DMF three times for one hour. Boc-aminooxyacetic 
acid (0.460 g, 2.4 mmoles) was then coupled using DIC (370 μL, 2.4 mmoles) for 10 
minutes as described255. The resin was washed with DCM and dried. Cleavage from the 
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resin and deprotection was achieved using 5 mL of 1% triisopropyl silane, 2.5% 
ethanedithiol, 2.5% water in trifluoroacetic acid (TFA) for 2.5 hours. The peptide was 
precipitated using 50 mL of 5% 2-mercaptoethanol in diethyl ether, centrifuged at 4800 
rpm for 10 minutes, resuspended in 5 mL of HPLC buffer A, and lyophilized. The crude 
residue was then purified by process scale RP-HPLC on a C18 column using a gradient 
of 5-20% B. Fractions containing the purified peptide 2 were identified by HPLC/MS, 
pooled, and lyophilized. Yield from 0.3 mmol scale: 120 mg, (0.19 mmol), 63%. 
 
Semisynthesis of Aminooxy-leptin 4 
Leptin(1-146) a-α-thioester 1 was dissolved to a concentration of 20 mg/mL in 6 
M guanidine hydrochloride, 100 mM sodium 2-mercaptoethane sulfonate, 200 mM 
sodium phosphate, 150 mM sodium chloride, pH 7.2. Peptide 2 (10-20 mg, 25 
equivalents) was added to 10 mg/mL, and the pH was adjusted to 7.2 using 1 N NaOH. 
After overnight reaction at room temperature, the crude mixture containing unfolded 
aminooxy-leptin derivative 3 was diluted to 0.25 mg/mL in 6 M guanidine hydrochloride, 
20 mM tris pH 7.4, 5 mM dithiothreitol. The product was then dialyzed at 4 °C 
sequentially against 6 M urea, 2.5 mM dithiothreitol, 2.5 mM 2-mercaptoethanol, 500 
μM aminooxyacetic acid, 20 mM tris pH 7.4, then against 4 and 2 M urea containing 5 
mM 2-mercaptoethanol, 500 μM aminooxyacetic acid, 20 mM tris pH 7.4, then against 
500 μM aminooxyacetic acid, 20 mM tris pH 7.4, and finally overnight against 20 mM 
tris pH 7.4, 5 mM oxidized glutathione, 0.5 mM reduced glutathione, 500 μM 
aminooxyacetic acid, 150 mM sodium chloride. The crude refolded mixture was purified 
on a C4 semiprep RP-HPLC column using a gradient of 45-60% buffer B (buffer A = 
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0.1% TFA in water, buffer B = 90% acetonitrile, 0.1% TFA in water.) Fractions 
containing pure refolded AOA-leptin 4 were identified by HPLC and ESI-MS and pooled 
and lyophilized into 250 μg aliquots. Yield from a 1 μmol scale: 5 mg, (0.3 μmol), 30%. 
 
Tryptic Digestion of Aminooxy-leptin 4 and Recombinant Leptin 
20 μg of sequencing grade trypsin (Promega, Madison, WI) was dissolved in 100 
μL of trypsin resuspension buffer (provided by the manufacturer), and incubated at 30 °C 
for 15 minutes. The trypsin solution was added to 150 μg of either aminooxy-leptin 4 
(dissolved in 15 mM HCl) or recombinant leptin (Amgen, Thousand Oaks, CA), and the 
pH was adjusted to 8.3 using 1 M sodium bicarbonate. The reaction was incubated at 37 
°C for 3 hours, and analyzed by analytical RP-HPLC on a C4 analytical column using a 
gradient of 0-100% B. Peaks were collected and identified by ESI-MS. 
 
Synthesis of 19FBA-leptin 5 
Aminooxy-leptin 4 (5 mg, 0.3 mmole) was dissolved in 2 mL of 15 mM HCl. 250 
μL 1 M sodium acetate pH 4.5 was added, followed by 250 μL of 10 mM 4-
fluorobenzaldehyde in DMF. The reaction was vortexed, and incubated at 4 °C overnight. 
The reaction was then purified by C4 semipreperative RP-HPLC on a gradient of 46-61% 
B. Fractions containing pure FBA-leptin 5 were pooled and lyophilized, yielding 1.7 mg 




Synthesis and Reformulation of 18F-FBA 
The radiosynthesis of 18F-FBA was accomplished essentially as previously 
described, however in order to facilitate labeling of leptin, which precipitates in solutions 
containing a high proportion of organic solvents, it was reformulated into 5 μL of DMF. 
The precursor (4-formylphenyl)trimethylammonium trifluoromethanesulfonate was 
synthesized as previously described155. This precursor was dried under vacuum and stored 
under argon atmosphere.  Cyclotron produced 18F in 18O water was loaded onto a QMA 
light cartridge (Waters), which had been preconditioned with 5 mL 0.5M potassium 
carbonate and 10 mL water. The cartridge was eluted with a solution of 20 mg kryptofix 
222 (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane), 2 mg potassium 
carbonate in 1:1 acetonitrile:water into a 3 mL reactivial (Pierce, Rockford, IL) equipped 
with a stir bar. The resulting solution was evaporated at 95 °C with a gentle nitrogen 
stream, and dried azeotropically using 3 x 1 mL dry acetonitrile. The resulting solid was 
resuspended in 400 μL of dry DMSO and transferred to a second 3 mL reactivial 
equipped with a stir bar and containing 1-2 mg of (4-formylphenyl)trimethylammonium 
trifluoromethanesulfonate. The vial was incubated for 8 minutes at 120 °C, and then 
cooled to room temperature. The reaction was then diluted with 1.5 mL of water, and 
filtered through a GHP filter (Pall, East Hill, NY) and loaded on a Waters μBondapak 
C18 (7.8 x 300 mm) semiprep column, and eluted isocratically using 13:87 
acetonitrile:water with 0.1% TFA at a flow rate of 3 mL/min. The peak eluting at 14 
minutes was diluted with 15 mL water, and loaded onto a C18 sep-pak plus cartridge 
(Waters). The cartridge was then eluted with 1 mL of diethyl ether. A small amount of 
DMF (5 μL) was added during this step to minimize loss of the FBA during evaporation. 
 133 
The diethyl ether was then evaporated at 45° C, leaving a small organic residue (about 5-
10 μL in a typical reaction). The product had the same Rf in 3:1 hexanes:ethyl acetate as 
authentic 4-fluorobenzaldehyde (0.65) and the same retention time on C18 HPLC as the 
authentic sample. Starting from 9.25-13 GBq, typically 1.3-1.85 GBq of reformulated 
18FBA could be recovered with a synthesis time of 90 minutes. 
 
Rate of Oximation of Aminooxyleptin 4 with 18F-FBA 
Lyophilized aminooxy-leptin 4 (150 μg, 9.1 nmol) was dissolved in 55 μL 15 mM 
HCl, and 15 μL of either 0.5 M sodium acetate pH 4.5 or anilinium acetate pH 4.5 was 
added, giving a final volume of 70 μL (final concentration of 4 = 125 μM). 2 μL of 18F-
FBA in DMF (prepared as described in the supporting information) was added to each 
reaction, which was vortexed and placed on ice. Aliquots of the reaction were spotted on 
TLC plates at the indicated times and run with 4:1 DCM methanol with 2% acetic acid. 
18F-FBA leptin 5 was retained at the origin while 18F-FBA migrated at the solvent front. 
At t = 30 minutes, a small portion of the anilinium acetate reaction was injected on a C4 
analytical HPLC column and eluted on a 0-100% B gradient over 30 minutes. The 18F-
FBA eluted at 3.5 minutes while the 18F-FBA-leptin 5 eluted at 21 minutes on this 
gradient.  
 
Synthesis of 18F-FBA-leptin 5 
Lyophilized aminooxy-leptin 4 (500 μg, 30 nmol) was dissolved in 100 μL of 15 
mM HCl. To this solution was added 25 μL of 0.5 M anilinium acetate, pH 4.5. The 
aforementioned DMF solution of 18F-FBA was then added, and the mixture was vortexed 
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and incubated on ice for 15 minutes. The reaction was then purified through two micro 
bio-spin P-6 columns (Biorad, Hercules, CA), which had been pre-equilibrated with PBS 
according to the manufacturer’s instructions. The eluate from the columns was filtered 
though a 0.22 μM filter. The purity of the oxime product was analyzed by both RP-HPLC 
using a 0-100% B gradient on a C4 analytical column, and by iTLC (ITLC SG silica 
impregnated glass fiber sheets, Pall, East Hill, NY) using 1% acetic acid in water as an 
eluant. While the labeling yield as detected by HPLC or iTLC was typically over 50%, 
the recovered yield was generally 25%, probably due to precipitation of the protein. 
Starting from 9.25-13 GBq of aqueous K18F, typically 93-200 MBq of 18F-FBA-leptin 5 
was recovered with a total synthesis time of 120 minutes. The total amount of protein in 
the final sample was determined using the BCA assay (BCA assay micro plate kit, Pierce, 
Rockford, MD). The specific activity at the end of synthesis was 9.25-13 GBq/μmol 
(n=4). 
 
Stability of 18F-FBA-leptin 5 in vitro 
Approximately 200 kBq of 18F-FBA-leptin 5 in 2 μL was diluted in either 100 
mM sodium acetate pH 4.5 (10 mM sodium phosphate, 140 mM sodium chloride, pH 
7.4), PBS, or mouse serum. After 60 minutes a sample of each was injected on a C4 
analytical HPLC. Integration of the radiochemical HPLC peaks was used to estimate the 
purity of the sample, and if no other peaks could be detected above background the 




Synthesis of Isopropylidene-aminooxyacetic acid, succinimide ester (6) 
Isopopylidene-aminooxyacetic acid was synthesized as previously described162. 
To 500 mg (3.8 mmol) of isopopylidene-aminooxyacetic acid in 30 mL 
dichlooromethane, cooled on ice, was added 3.8 mmol (439 mg) N-hydroxysuccinimide, 
and 3.8 mmol dicyclohexylcarbodiimide (782.8 mg). The mixture was stirred and 
allowed to warm to room temperature overnight. The reaction was filtered to remove 
insoluble dicyclohexylurea. The mixture was washed with 1N HCl, water, 1% sodium 
bicarbonate, then dried over sodium sulfate. The reaction was then filtered and 
evaporated to dryness, and triturated with dichloromethane to remove residual 
dicyclohexylurea. Yield 450 mg. 1.97 mmol, 52%. 1H NMR (400 MHz, CDCl3) δ 4.90 (s, 
2H), 2.84 (s, 4H), 1.92 (s, 2H), 1.88 (s, 2H). 
 
Conjugation of Isopropylidene-aminooxyacetic, succinimide ester (6) to leptin  
To 20 uL of leptin solution (13.1 mg/mL, 16.4 nmol total) was added 32 uL of 
100 mM sodium phosphate, pH 7.5, to generate a 5 mg/mL solution. Two 25 uL aliquots 
were prepared, and to each aliquot was added either 32.8 or 164 nmol isopropylidene-
aminooxyacetic acid-NHS (corresponding to 7.5 or 37 µg) in 2.5 µL DMF. The reactions 
was allowed to stand for 5-6 hours and then analyzed by RP-HPLC and ESI-MS. 
 
Preparation of aminooxyleptin by lysine side chain modification strategy 
To 30 µL of leptin solution at 13.1 mg/mL was added 48 µL of 100 mM sodium 
phosphate pH 7.5, and 22.5 µg of isopropylidene-aminooxyacetic acid, succinimide ester 
(6) in 5 µL DMF. The reaction was allowed to proceed at room temperature overnight, 
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then chilled on ice. The reaction was diluted 1:1 with 1M methoxylamine 
hemihydrochloride, and allowed to stand on ice for five hours. The reaction was then 
analyzed by HPLC and ESI-MS. 
 
Micro-PET imaging experiments 
Imaging was conducted using a MicroPET (Focus TM 220, CTI Concord 
Microsystems, LLC) camera, with a bore size of 22 cm and an axial field of view of 7.6 
cm. This enables imaging of the entire mouse. The resolution at the center of field of 
view (FOV) is <1.3 mm.  Mice ranged in age from four to seven months of age. 
Following induction of anesthesia with ketamine, each mouse was injected with 
3.7-5.4 MBq of 18F-FBA-leptin 5 or 68Ga-DOTA-leptin in the tail vein. Rats were injected 
with 6-10 MBq of 68Ga-DOTA-leptin. The distribution of radioactivity was studied by 
acquiring dynamic imaging for 30 - 60 minutes. 3D histograms of emission data were 
generated (span3, rig difference 47) using dead time correction. Images were 
reconstructed using OSEM2D algorithm without any attenuation or scatter correction. All 
data were analyzed on PMOD software (Zurich, Switzerland). Regions of interest were 
drawn by two independent operators, with similar results.  
 
Metabolite analysis of blood, kidney, and urine by radiochemical HPLC 
 Approximately 20 MBq of 68Ga -DOTA-leptin or 18F-FBA-leptin was injected into 
the appropriate mice via the tail vein after induction of anesthesia with ketamine-
xylazine. At the indicated time point, the animals were sacrificed, and the blood, urine, 
and kidneys harvested. Alternately, urine samples could be recovered by massaging the 
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bladder of the mice. Blood samples were centrifuged for 10 min at 8000 RPM (x g) prior 
to injection on HPLC. Kidney samples were solubilized by homogenization in 25 mM 
Tris pH 7.8, 1% triton X-100, 0.25% BSA, with one Compete mini EDTA-free protease 
inhibitor tablet (Roche) added per 10 mL, and centrifuged for 10 minutes at 8000 RPM 
prior to injection on HPLC.  
 
Leptin ELISA in urine samples 
Urine samples for ELISA were collected at 16 weeks of age. Urine samples from 
megalinlox/lox,ApoEcre and megalinlox/lox were diluted 10 fold in calibrator diluent of the 
mouse Elisa assay kit (R & D biosystems). A standard curve was build with known 
amounts of mouse recombinant leptin diluted in calibrator diluent and 10% urine from 
leptin deficient ob/ob mice. Instructions from the manufacturer were followed. Samples 
were measured in duplicate, and the assay sensitivity was 0.4 ng/ml.  
 
Western blotting from urine samples 
 After concentration (10 fold from the starting volume) of the urine of 
megalinlox/lox,ApoEcre and megalinlox/lox using vivaspin concentrators (Sartorius), samples 
were boiled at 95 C in loading buffer with 10% 2-mercaptoethanol. 30 microliters of each 
sample were loaded on a 5-12% acrylamide gel (Biorad) and then transferred to 
nitrocellulose membranes for western blot analysis. Blots were blocked in TBST and 5% 
milk and then incubated overnight in TBST and 5% milk with rabbit polyclonal anti-
leptin antibody A-20 (Santa Cruz) diluted 1:500. After wash with TBST blot was 
incubated with a secondary antibody anti-rabbit IgG conjugated with HRP (GE 
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Healthcare) and ECL reaction performed using ECL plus western blotting detection 
system kit (GE Healthcare). 
 
Mouse biodistribution experiments 
 Approximately 10-15 KBq of 125I-leptin (New England Nuclear, 81.4 GBq/umol, 
20 uL of the solution provided by the manufacturer) was diluted in 300 uL of sterile PBS 
and injected in the tail vein of the appropriate mouse strains in the presence or absence of 
50 uL of murine leptin solution (13.1 mg/mL, Amgen/Amylin). After 15 minutes, the 
animals were sacrificed, and tissues were collected and weighed. Radioactivity associated 
with each sample was counted in a gamma counter with corresponding standards and 
blanks, and residual activity from each injection.  The total injected dose was computed 
by preparing a standard of 20 uL of the manufacturers solution, and subtracting the 
residual dose remaining in the syringe post injection, and the radioactivity in the tail of 
the animal. 
 
Subcloning of Rhesus-leptin in a pET 15b vector 
 Rhesus leptin was subcloned into a PET15b vector, to facilitate purification using 
the His6 tag encoded for in the vector. A plasmid containing a synthetic gene, codon 
optimized for expression in bacteria, encoding the 146 amino acids of intact rhesus leptin 
following a methionine, was ordered from Integrated DNA technologies. The 2 µg of 
DNA obtained from the manufacturer was resuspended in 200 µL TE buffer. The cDNA 
encoding rhesus leptin was amplified by PCR from using forward and reverse primers 
(GGAATTCCATATGGTGCCAATCCAGAAAGTTCA and 
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CGGGATCCTTAACAACCCGGAGACAGGTC, respectively) encoding the NdeI and 
BamHI restriction sites. The PCR reaction was then purified by gel extraction. The PCR 
product and the PET15b vector was digested with NdeI and BamHI, and the vector was 
treated with calf intestinal phosphatase. The vector was then purified by gel extraction, 
and the PCR product using a PCR purification kit (Qiagen). The rhesus leptin PCR 
product was then ligated into the PET15b vector, and transformed into DH5α E. coli. The 
identity of the correct plasmids were screened by digestion with NdeI and BamHI, and 
confirmed by sequencing. 
 
Expression and purification of rhesus leptin 
 Expression of rhesus leptin was similar to a previously described protocol256. 
PET15b-Rhesus leptin plasmid was transformed into BL21(DE3) E. coli. An overnight 
culture was prepared in LB broth, which was diluted the following day by a factor of 100 
into 6 X 1L shaking flasks. The bacteria grew at 37°C with shaking at 250 RPM, and 
protein expression was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) at an OD590 of 0.8. After six hours of induction, the cells were harvested by 
centrifugation. From a typical prep, 30g of biomass could be obtained. Initial experiments 
revealed the presence of an approximately 16 kDa protein in the insoluble fraction, in 
induced but not uninduced cells, and thus preparation of the protein from inclusion bodies 
was used in future experiments. 
 The cells were resuspended in two volumes lysis buffer consisting of 1% triton, 
50 mM sodium phosphate buffer, pH 7.0, 200 mM sodium chloride supplemented with 
one complete protease inhibitor tablet, EDTA free (Roche, Basel, Switzerland) per 50 mL 
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of buffer. The cells were lysed by passage through a French Press (Emulsiflex C5 
homogenizer, Avestin, Ottawa, Canada.) The inclusion bodies were separated by 
centrifugation at 16,000 rpm for 30 minutes, and washed with an equal volume of lysis 
buffer. The pellet was subsequently resuspended overnight in one volume (relative to the 
cell pellet) of resuspension buffer consisting of 8 M urea, 10 mM imidazole, 500 mM 
sodium chloride, 100 mM sodium phosphate, pH 7.5. This suspension was centrifuged 
again at 16,000 RPM for 30 minutes to remove insoluble debris, and applied to 25 mL of 
Ni-NTA beads which were pre-equilibrated with resuspension buffer supplemented with 
10 mM imidazole. The beads were then washed with resuspension buffer supplemented 
with 20 mM imidazole, and the fusion protein was eluted from the column with 5 x 20 
mL fractions of resuspension buffer supplemented with 500 mM imidazole. The fractions 
were analyzed by SDS-PAGE and those containing the fusion protein were pooled. The 
protein was then refolded by dropwise infusion of 0.1M Tris pH 7.4 at 1 mL/min over 
approximately 90 minutes. Reduced and oxidized glutathione were added to 10 and 1 
mM, respectively, and the solution was allowed to stir overnight at 4 °C. The solution 
was then centrifuged at 16,000 RPM for 30 minutes to remove insoluble debris, and then 
dialyzed against thrombin cleavage buffer consisting of 50 mM tris pH 8.3, 150 mM 
NaCl, 2.5 mM CaCl2 in order to remove imidazole. The resulting solution was again 
centrifuged to remove insoluble debris, and 100 units of thrombin (Sigma) was added to 
the supernatant. Following overnight cleavage at 4 °C, the resulting solution was purified 
by process scale C4 RP-HPLC on a 47-62%B gradient. The fractions containing the 
intact rhesus leptin were then resuspended in 6M guandine, 100 mM Tris pH 8.0, and 
purified by gel filtration on an S75 10/300 GL column, using 10 mM sodium phosphate, 
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140 mM NaCl, pH 7.4 as an eluant. From a typical 6L prep, 2 – 3 mg of rhesus leptin 
could be obtained using this protocol. The sequence of the final protein is GSHM-rhesus 
leptin(1-146). 
 
Rhesus macaque PET-CT imaging experiments 
On experiment days, the subjects were individually transported to the PET center 
in a purpose - built transfer cage. They were then injected with ketamine (10 mg/kg, i.m.) 
and atropine (0.05 mg/kg, i.m). Subjects were then intubated and anesthesia was induced 
with isoflurane (3%). Subjects’ vital signs (respiratory rate, heart rate, temperature and 
pulse oximetry) were monitored throughout, anesthesia was typically then maintained at 
1.5-2% isoflurane for the remainder of the experiment.  
The subject was placed supine on a heating pad (37oC) in the bed of the PET 
scanner for the remainder of the experiment. Primate PET/CT scans were performed 
using a GE Discovery LS PET/CT scanner (GE Healthcare, Waukesha, Wis.). A low-
dose CT scan was obtained and the scanner bed was moved into PET 
position.  Competing cold leptin was administered by a femoral catheter 10 min prior to 
injection of the radiotracer. Immediately following an intravenous injection of 0.25-1 
mCi of 68Ga-DOTA-leptin, 4 sequential 18 min whole-body images were obtained (3 
beds, 6 minutes each) in 3D acquisition mode. Images were reconstructed using the 
FORE-Iterative reconstruction method. 
 Following completion of the transmission scan, isoflurane was discontinued and 
the subject was extubated when gagging reflex is observed, and carefully observed until 
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